

Guidelines of care for the management of psoriasis and

Journal of the American Academy of Dermatology

58, 826-850

DOI: [10.1016/j.jaad.2008.02.039](https://doi.org/10.1016/j.jaad.2008.02.039)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The impact of treatment with tumour necrosis factor- α antagonists on the course of chronic viral infections: a review of the literature. <i>British Journal of Dermatology</i> , 2008, 159, 1217-1228.	1.4	154
2	Adalimumab in dermatology. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 618-625.	1.1	33
3	Ustekinumab for chronic plaque psoriasis. <i>Lancet, The</i> , 2008, 371, 1639-1640.	6.3	46
4	Chemotherapy for malignant pleural mesothelioma. <i>Lancet, The</i> , 2008, 371, 1640-1642.	6.3	23
6	Challenges in the treatment and management of psoriasis. <i>NursePrescribing</i> , 2008, 6, 343-348.	0.1	0
7	Keynote lecture: psoriasis update. <i>Expert Review of Dermatology</i> , 2008, 3, S3-S9.	0.3	0
8	TNF- α Blocker-Induced Psoriasiform Dermatitis. <i>Psoriasis Forum</i> , 2008, 14a, 8-18.	0.1	1
9	Biologics in the management of psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 111.	0.8	8
10	Clinical Review a Practical Approach to the Use of Etanercept. <i>Psoriasis Forum</i> , 2009, 15a, 36-40.	0.1	0
11	PsorÃªase na infÃ¢ncia e na adolescÃªncia. <i>Anais Brasileiros De Dermatologia</i> , 2009, 84, 09-20.	0.5	22
12	Recurrent Angioedema Associated with Efalizumab. <i>Acta Dermato-Venereologica</i> , 2009, 89, 665-666.	0.6	6
13	Etanercept in the treatment of plaque psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 77.	0.8	10
14	The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	54
15	Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update. <i>Journal of Inflammation Research</i> , 2009, 2, 29.	1.6	7
16	Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. <i>Dermatology</i> , 2009, 219, 158-161.	0.9	6
17	Ustekinumab. <i>MAbs</i> , 2009, 1, 216-221.	2.6	49
18	Treatment guidelines for psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 329-342.	0.3	5
19	Targeting NF- κ B with a Natural Triterpenoid Alleviates Skin Inflammation in a Mouse Model of Psoriasis. <i>Journal of Immunology</i> , 2009, 183, 4755-4763.	0.4	80

#	ARTICLE	IF	CITATIONS
21	Biologics in the Treatment of Psoriasis: Clinical and Economic Overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S49-S57.	0.6	22
22	Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1456-1465.	0.9	20
23	Practical Aspects of Prescribing a Biologic. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S93-S101.	0.6	2
24	Progressive Multifocal Leukoencephalopathy, Efalizumab, and Immunosuppression. <i>Archives of Dermatology</i> , 2009, 145, 937-42.	1.7	74
25	Inflammatory bowel disease and hepatitis A and C. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, 1082-1093.	0.9	20
26	Maladies inflammatoires chroniques intestinales et hépatites B et C. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, e1-e14.	0.9	1
27	Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. <i>Archives of Dermatological Research</i> , 2009, 301, 429-442.	1.1	14
28	Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. <i>British Journal of Dermatology</i> , 2009, 160, 670-675.	1.4	72
29	Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. <i>British Journal of Dermatology</i> , 2009, 161, 723-731.	1.4	72
30	British Association of Dermatologists'™ guidelines for biologic interventions for psoriasis 2009. <i>British Journal of Dermatology</i> , 2009, 161, 987-1019.	1.4	412
31	Psoriasis market. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 767-768.	21.5	22
32	Long-term safety of biologics in dermatology. <i>Dermatologic Therapy</i> , 2009, 22, 2-21.	0.8	13
33	Key opinion leaders: where they come from and how that affects the drugs you prescribe. <i>Dermatologic Therapy</i> , 2009, 22, 262-268.	0.8	43
34	Is there truly a risk of lymphoma from biologic therapies?. <i>Dermatologic Therapy</i> , 2009, 22, 418-430.	0.8	55
35	Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?. <i>Dermatologic Therapy</i> , 2009, 22, 431-440.	0.8	40
36	European S3 Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.	1.3	683
37	Treatment strategies for early psoriatic arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 271-282.	0.9	16
38	No more pens: what the 2009 Pharmaceutical Research and Manufacturer's Association code changes really mean. <i>Clinics in Dermatology</i> , 2009, 27, 346-349.	0.8	1

#	ARTICLE	IF	CITATIONS
39	Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. Actas Dermo-sifiliográficas, 2009, 100, 386-413.	0.2	73
40	Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. Journal of the American Academy of Dermatology, 2009, 60, 1077-1080.	0.6	21
41	Increasing use of more potent treatments for psoriasis. Journal of the American Academy of Dermatology, 2009, 60, 478-481.	0.6	25
42	Hidradenitis suppurativa: A comprehensive review. Journal of the American Academy of Dermatology, 2009, 60, 539-561.	0.6	579
43	Treatments for psoriasis and the risk of malignancy. Journal of the American Academy of Dermatology, 2009, 60, 1001-1017.	0.6	195
44	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2009, 60, 643-659.	0.6	419
45	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2009, 61, 451-485.	0.6	505
46	Comorbidities in Patients with Psoriasis. American Journal of Medicine, 2009, 122, 1150.e1-1150.e9.	0.6	161
47	Topical Clobetasol Propionate in the Treatment of Psoriasis. American Journal of Clinical Dermatology, 2009, 10, 397-406.	3.3	45
48	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. Actas Dermo-sifiliográficas, 2009, 100, 386-413.	0.2	14
49	Ustekinumab. Drugs, 2009, 69, 1141-1152.	4.9	30
50	Clinical Spectrum and Severity of Psoriasis. Current Problems in Dermatology, 2009, 38, 1-20.	0.8	56
51	Ustekinumab. BioDrugs, 2009, 23, 53-61.	2.2	25
52	Ustekinumab: a guide to its use in plaque psoriasis. Drugs and Therapy Perspectives, 2009, 25, 5-8.	0.3	1
53	Economic burden of psoriasis compared to the general population and stratified by disease severity. Current Medical Research and Opinion, 2009, 25, 2429-2438.	0.9	86
54	Tratamiento de la psoriasis en placas moderada y grave con etanercept. Piel, 2009, 24, 105-113.	0.0	4
55	Evaluation and Management of Psoriasis: An Internist's Guide. Medical Clinics of North America, 2009, 93, 1291-1303.	1.1	50
57	New insights into the pathogenesis and genetics of psoriatic arthritis. Nature Clinical Practice Rheumatology, 2009, 5, 83-91.	3.2	112

#	ARTICLE	IF	CITATIONS
59	Diagnosis and Management of Psoriatic Arthritis. Journal of the Dermatology Nurses' Association, 2009, 1, 283-293.	0.1	1
60	The DESIRE study – psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice. European Journal of Dermatology, 2009, 19, 581-585.	0.3	13
61	You're the Flight Surgeon. Aviation, Space, and Environmental Medicine, 2009, 80, 501-502.	0.6	1
62	Pathobiology of Chronic Inflammatory Skin Diseases: Interplay Between Keratinocytes and Immune Cells as a Target for Anti-Inflammatory Drugs. Current Drug Metabolism, 2010, 11, 210-227.	0.7	69
63	Advantages in early recognition and treatment of psoriatic arthritis. International Journal of Clinical Rheumatology, 2010, 5, 461-473.	0.3	1
64	Chronic Administration of Cyclosporine A Changes Expression of BDNF and TrkB in Rat Hippocampus and Midbrain. Neurochemical Research, 2010, 35, 1098-1104.	1.6	21
65	Tratamiento de la psoriasis moderada-grave. Piel, 2010, 25, 161-170.	0.0	1
66	Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis. Seminars in Arthritis and Rheumatism, 2010, 40, 233-240.	1.6	239
67	Narrow-band UVB phototherapy of nasal polyps: Results of a pilot study. Journal of Photochemistry and Photobiology B: Biology, 2010, 100, 123-127.	1.7	5
68	An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 578-586.	1.3	12
69	Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1135-1143.	1.3	28
70	Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1371-1377.	1.3	39
71	EADV preceptorship: advances in dermatology. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 2-24.	1.3	11
72	Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. British Journal of Pharmacology, 2010, 160, 810-820.	2.7	120
73	Managing inflammatory arthritides: Role of the nurse practitioner and physician assistant. Journal of the American Academy of Nurse Practitioners, 2010, 22, 382-392.	1.4	11
74	Tumor necrosis factor- α -converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients. Photodermatology Photoimmunology and Photomedicine, 2010, 26, 36-40.	0.7	5
75	Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study. Journal of Dermatology, 2010, 37, 299-310.	0.6	169
76	A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. International Journal of Dermatology, 2010, 49, 1368-1375.	0.5	35

#	ARTICLE	IF	CITATIONS
77	Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. British Journal of Dermatology, 2010, 162, 1117-1123.	1.4	13
78	Guidance on the use of biological agents in the treatment of oral mucosal disease. British Journal of Dermatology, 2010, 162, 1410-1411.	1.4	6
79	Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. British Journal of Dermatology, 2010, 162, 1349-1358.	1.4	39
80	Bevacizumab-induced hand-foot syndrome: circumscribed type. British Journal of Dermatology, 2010, 162, 1411-1413.	1.4	8
81	Targeted phototherapy of plaque-type psoriasis using ultraviolet B-light-emitting diodes. British Journal of Dermatology, 2010, 163, 167-173.	1.4	31
82	A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. British Journal of Dermatology, 2010, 163, 402-411.	1.4	99
83	No Increased Risk of Cancer after Coal Tar Treatment in Patients with Psoriasis or Eczema. Journal of Investigative Dermatology, 2010, 130, 953-961.	0.3	86
84	Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clinical, Cosmetic and Investigational Dermatology, 2010, 3, 25.	0.8	4
85	Adalimumab Treatment and Work Productivity in Patients with Moderate to Severe Psoriasis: Results from a Prospective Clinical Trial. Psoriasis Forum, 2010, 16a, 2-6.	0.1	0
86	Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis. Psoriasis Forum, 2010, 16a, 3-11.	0.1	0
87	Pediatric Psoriasis: An Emphasis on Treatment. Psoriasis Forum, 2010, 16a, 26-35.	0.1	0
88	Guidelines on the Management of Psoriasis in South Africa. South African Medical Journal, 2010, 100, 255.	0.2	19
89	Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evidence, 2010, 5, 11.	4.7	11
90	Value of Enthesal Ultrasonography and Serum Cartilage Oligomeric Matrix Protein in the Preclinical Diagnosis of Psoriatic Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2010, 3, CMAMD.S4461.	0.3	20
91	ImunopatogÃªnese da psorÃªase. Anais Brasileiros De Dermatologia, 2010, 85, 747-749.	0.5	15
92	Comorbidities in Psoriasis. Psoriasis Forum, 2010, 16a, 23-30.	0.1	0
93	Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis. Journal of Managed Care Pharmacy, 2010, 16, 402-416.	2.2	17
94	The psoriasisform reaction pattern. , 2010, , 71-91.e18.		4

#	ARTICLE	IF	CITATIONS
96	Strategies for Treatment With Anti-Tumor Necrosis Factor Agents in Psoriasis. <i>Archives of Dermatology</i> , 2010, 146, 186-8.	1.7	3
97	Updated Turkish Guidelines for the Management of Psoriasis with Biologic Agents. <i>Turkderm</i> , 2010, 44, 105-112.	0.0	7
98	The First Decade of Biologic TNF Antagonists in Clinical Practice: Lessons Learned, Unresolved Issues and Future Directions. <i>Current Directions in Autoimmunity</i> , 2010, 11, 180-210.	8.0	224
99	Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. <i>BMJ: British Medical Journal</i> , 2010, 340, c147-c147.	2.4	195
100	Epidemiology of Moderate-to-Severe Plaque Psoriasis in a Canadian Surveyed Population. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010, 14, 167-174.	0.6	15
101	Recent Trends in Systemic Psoriasis Treatment Costs. <i>Archives of Dermatology</i> , 2010, 146, 46-54.	1.7	73
102	Photoleukomelanoderma Possibly Caused by Etretinate in a Patient with Psoriasis. <i>Acta Dermato-Venereologica</i> , 2010, 90, 85-86.	0.6	9
103	Critical Appraisal of Quality of Clinical Practice Guidelines for Treatment of Psoriasis Vulgaris, 2006-2009. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2389-2395.	0.3	27
104	A Comprehensive Analysis of Pattern Recognition Receptors in Normal and Inflamed Human Epidermis: Upregulation of Dectin-1 in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2611-2620.	0.3	68
106	Use of Kv1.3 Blockers for Inflammatory Skin Conditions. <i>Current Medicinal Chemistry</i> , 2010, 17, 2882-2896.	1.2	17
107	Treating Psoriasis with Etanercept in Italian Clinical Practice. <i>Clinical Drug Investigation</i> , 2010, 30, 507-516.	1.1	12
108	Autoimmune hepatitis in two psoriasis patients treated with inflixmab. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, e43-e44.	0.6	28
109	Acute localized exanthematous pustulosis induced by docetaxel. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, e44-e46.	0.6	15
110	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 114-135.	0.6	311
111	Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 228-234.	0.6	46
112	Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. <i>Cytokine</i> , 2010, 49, 163-170.	1.4	44
115	Comorbidities in Psoriasis Patients. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 10-15.	1.6	99
116	Psoriasis: what we have learned from mouse models. <i>Nature Reviews Rheumatology</i> , 2010, 6, 704-714.	3.5	190

#	ARTICLE	IF	CITATIONS
117	Management of Psoriatic Arthritis. , 2010, , 55-69.		1
118	Topical treatment of psoriasis. Expert Opinion on Pharmacotherapy, 2010, 11, 1999-2009.	0.9	57
119	Spondyloarthritides: evolving therapies. Arthritis Research and Therapy, 2010, 12, 221.	1.6	13
120	Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Current Medical Research and Opinion, 2010, 26, 2385-2392.	0.9	51
121	Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology, 2010, 11, 3-9.	3.3	4
122	Psoriasis: Targeting Therapy Towards the Inflammatory Cascade. American Journal of Clinical Dermatology, 2010, 11, 11-13.	3.3	6
123	Adverse Effects of Biological Agents in the Treatment of Psoriasis. American Journal of Clinical Dermatology, 2010, 11, 35-37.	3.3	13
124	Advances in the treatment of moderate-to-severe plaque psoriasis. American Journal of Health-System Pharmacy, 2011, 68, 795-806.	0.5	27
125	BIOBADADERM, the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology: First Report. Actas Dermo-sifiligráficas, 2011, 102, 132-141.	0.2	4
126	Inflammatory posterior interosseous nerve palsy in a patient with psoriatic arthropathy. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2011, 64, e205-e207.	0.5	2
127	Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). Journal of Dermatological Science, 2011, 63, 154-163.	1.0	189
128	Opinion of Spanish Dermatologists Regarding the Use of Biologic Therapy in Patients With Moderate to Severe Psoriasis. Actas Dermo-sifiligráficas, 2011, 102, 706-716.	0.2	3
129	Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to Efalizumab. Free Radical Research, 2011, 45, 585-599.	1.5	12
130	The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Review of Clinical Immunology, 2011, 7, 9-13.	1.3	40
131	Ustekinumab. Drugs, 2011, 71, 1733-1753.	4.9	47
132	Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life. Clinical Drug Investigation, 2011, 31, 51-60.	1.1	13
135	Is tuberculin skin testing reliable during anti-tumor necrosis factor-alfa therapy? A case report and review of the literature. Journal of the American Academy of Dermatology, 2011, 65, 195-197.	0.6	39
136	A review of phototherapy protocols for psoriasis treatment. Journal of the American Academy of Dermatology, 2011, 64, 936-949.	0.6	128

#	ARTICLE	IF	CITATIONS
137	Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 546-551.	0.6	127
138	Low prevalence of psoriasis among children and adolescents in a large multiethnic cohort in southern California. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 957-964.	0.6	43
139	Ocular psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1202-1212.	0.6	93
140	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 137-174.	0.6	398
141	A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2041-2054.	0.9	56
142	Clinical efficacy of propylthiouracil and its influence on prolactin in psoriatic patients. <i>Clinical Biochemistry</i> , 2011, 44, 1209-1213.	0.8	12
143	Dermatologistâ€œPatient In-Office Discussions of Psoriasis: Focus on Quality of Life. <i>Psoriasis Forum</i> , 2011, 17a, 290-297.	0.1	0
144	A Strategic Approach to Setting the Research Agenda in Psoriasis. <i>Psoriasis Forum</i> , 2011, 17a, 97-102.	0.1	3
145	Ustekinumab: differential use in psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2011, 4, 93.	0.8	4
146	Biologic Therapy and the Risk of Malignancy in Psoriasis. <i>Psoriasis Forum</i> , 2011, 17a, 238-253.	0.1	6
147	Community-Centered Family Health History: A Customized Approach to Increased Health Communication and Awareness. <i>Progress in Community Health Partnerships: Research, Education, and Action</i> , 2011, 5, 113-122.	0.2	18
148	C-Reactive Protein and Cardiovascular Disease in Psoriasis. <i>Psoriasis Forum</i> , 2011, 17a, 24-32.	0.1	0
149	Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. <i>Drug Design, Development and Therapy</i> , 2011, 5, 41.	2.0	18
150	Care of Generalized Psoriasis in Elderly Patients beyond Topical Therapy: A Review and a Proposed Algorithm. <i>Psoriasis Forum</i> , 2011, 17a, 105-116.	0.1	0
151	Secondary Leprosy Infection in a Patient With Psoriasis During Treatment With Infliximab. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 269-271.	0.5	10
153	Long-term, continuous dosing of etanercept in patients with plaque psoriasis. <i>Expert Review of Dermatology</i> , 2011, 6, 361-373.	0.3	1
155	Tele-assessment of Psoriasis Area and Severity Index: A study of the accuracy of digital image capture. <i>Australasian Journal of Dermatology</i> , 2011, 52, 259-263.	0.4	21
156	Etanercept therapy in a hepatitis B virus (HBV)â€œpositive psoriatic patient developing a monoclonal gammopathy of undetermined significance. <i>International Journal of Dermatology</i> , 2011, 50, 999-1001.	0.5	4

#	ARTICLE	IF	CITATIONS
157	How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology. <i>International Journal of Dermatology</i> , 2011, 50, 114-118.	0.5	1
158	Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 7-19.	1.1	28
159	Clinical, power Doppler sonography and histological assessment of the psoriatic plaque: short-term monitoring in patients treated with etanercept. <i>British Journal of Dermatology</i> , 2011, 164, 33-37.	1.4	50
160	Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. <i>British Journal of Dermatology</i> , 2011, 165, 375-382.	1.4	19
161	The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. <i>British Journal of Dermatology</i> , 2011, 165, 1066-1073.	1.4	103
162	Clinical efficacy of Avène hydrotherapy measured in a large cohort of more than 10,000 atopic or psoriatic patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 30-34.	1.3	39
163	Pregnancy outcomes in women with moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1041-1047.	1.3	53
164	Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1012-1020.	1.3	47
165	The Association of Psoriasis and Elevated Blood Lipids in Overweight and Obese Children. <i>Journal of Pediatrics</i> , 2011, 159, 577-583.	0.9	98
166	Pharmacogenetics of psoriasis. <i>Pharmacogenomics</i> , 2011, 12, 87-101.	0.6	24
167	Comparison of gene expression profiles reveals aberrant expression of FOXO1, Aurora A/B and EZH2 in lesional psoriatic skins. <i>Molecular Biology Reports</i> , 2011, 38, 4219-4224.	1.0	30
168	Decisive role of tumor necrosis factor- α for spongiosis formation in acute eczematous dermatitis. <i>Archives of Dermatological Research</i> , 2011, 303, 651-658.	1.1	19
169	Focus on skin cancer association and progression under TNF antagonist therapy. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1215-1222.	1.4	6
170	Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. <i>Rheumatology</i> , 2011, 50, 1700-1711.	0.9	127
171	Genetics of susceptibility and treatment response in psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 718-732.	3.5	55
172	Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series. <i>Journal of Dermatological Treatment</i> , 2011, 22, 75-78.	1.1	14
173	Management of Psoriasis in Africa and the Middle East: A Review of Current Opinion, Practice and Opportunities for Improvement. <i>Journal of International Medical Research</i> , 2011, 39, 1573-1588.	0.4	14
174	Impact of propylthiouracil on quality of life in psoriasis patients. <i>Indian Journal of Medical Sciences</i> , 2011, 65, 331.	0.1	4

#	ARTICLE	IF	CITATIONS
175	Management of psoriatic arthritis from the view of the dermatologist. <i>Nature Reviews Rheumatology</i> , 2011, 7, 588-598.	3.5	45
176	Herramientas en el diagnóstico y tratamiento de enfermedades dermatológicas, una actualización. <i>Revista Médica Clínica Las Condes</i> , 2011, 22, 722-726.	0.2	0
177	Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1007-1010.	0.3	47
178	Patient Preferences for Psoriasis Treatments. <i>Archives of Dermatology</i> , 2011, 147, 1285.	1.7	84
179	Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet. <i>Archives of Dermatology</i> , 2011, 147, 429.	1.7	96
180	An overview and update of psoriasis. <i>Nursing Standard (Royal College of Nursing (Great Britain):)</i> Tj ETQq1 1 0.784314 rgBT /Overlock 11	0.1	11
181	Teledermatological Monitoring of Psoriasis Patients on Biologic Therapy. <i>Acta Dermato-Venereologica</i> , 2011, 91, 680-685.	0.6	46
182	Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders. <i>Journal of Dermatological Treatment</i> , 2011, 22, 90-101.	1.1	9
183	Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting. <i>Archives of Dermatology</i> , 2012, 148, 487.	1.7	81
184	Rich Î²-Carotene Powder of the Alga <i>Dunaliella</i> Reduces the Severity of Chronic Plaque Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of the American College of Nutrition</i> , 2012, 31, 320-326.	1.1	21
185	Nutritive value of daily food rations of patients with psoriasis vulgaris: a preliminary report. <i>Advances in Dermatology and Allergology</i> , 2012, 5, 348-355.	1.0	6
186	Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-5.	3.0	17
187	The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-8.	0.9	41
188	Sample area for surface roughness determination of skin surfaces. , 2012, , .		3
189	Conjunctival Squamous Cell Carcinoma following Psoriasis Treatment. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012, 16, 365-367.	0.6	3
190	A Patient Decision Aid for Psoriasis Based on Current Clinical Practice Guidelines. <i>Archives of Dermatology</i> , 2012, 148, 718-23.	1.7	9
191	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. <i>European Journal of Dermatology</i> , 2012, 22, 762-769.	0.3	25
192	Etanercept: An Overview of Dermatologic Adverse Events. <i>Yearbook of Dermatology and Dermatologic Surgery</i> , 2012, 2012, 265-266.	0.0	0

#	ARTICLE	IF	CITATIONS
193	Current investigational drugs in psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 473-487.	1.9	33
194	Complete resolution of guttate psoriasis following autologous SCT for Ewing's sarcoma in a pediatric patient. <i>Bone Marrow Transplantation</i> , 2012, 47, 1585-1586.	1.3	8
195	Ethical considerations when prescribing biologics in dermatology. <i>Clinics in Dermatology</i> , 2012, 30, 492-495.	0.8	4
196	Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. <i>Dermatology and Therapy</i> , 2012, 2, 9.	1.4	29
197	Ustekinumab. Neoplasias y otros aspectos de seguridad. <i>Actas Dermo-sifiligráficas</i> , 2012, 103, 39-44.	0.2	3
198	Immunotherapies in Dermatologic Disorders. <i>Medical Clinics of North America</i> , 2012, 96, 565-582.	1.1	7
199	Ustekinumab en situaciones especiales: embarazo, interrupciones temporales (vacunaciones, cirugías) y otros. <i>Actas Dermo-sifiligráficas</i> , 2012, 103, 45-51.	0.2	2
200	Etanercept: efficacy and safety for approved indications. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 121-139.	1.0	61
201	An approach to psoriasis in general practice. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2012, 54, 88-92.	0.2	1
203	The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, e67-e76.	0.6	62
204	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 241-251.	0.6	157
205	Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 376-386.	0.6	40
206	The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. <i>British Journal of Dermatology</i> , 2012, 167, 1145-1152.	1.4	83
207	Current and Emerging Systemic Treatment Strategies for Psoriasis. <i>Drugs</i> , 2012, 72, 1867-1880.	4.9	35
208	Safety of anti-TNF agents in the treatment of psoriasis and psoriatic arthritis. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 548-560.	1.1	41
209	Effective Strategies for the Management of Pyoderma Gangrenosum. <i>Advances in Wound Care</i> , 2012, 1, 194-199.	2.6	29
210	Integrated Approach to Comorbidity in Patients With Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2012, 103, 1-64.	0.2	8
211	Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1349-1361.	0.6	40

#	ARTICLE	IF	CITATIONS
212	Oral Candida colonization and candidiasis in patients with psoriasis. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012, 114, 610-615.	0.2	18
213	Apremilast as a treatment for psoriasis. Expert Opinion on Pharmacotherapy, 2012, 13, 1761-1770.	0.9	11
214	Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings. Advances in Therapy, 2012, 29, 664-674.	1.3	81
216	Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis. Applied Health Economics and Health Policy, 2012, 10, 343-353.	1.0	14
217	Ustekinumab: a guide to its use in plaque psoriasis. Drugs and Therapy Perspectives, 2012, 28, 6-10.	0.3	0
218	Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1252-1261.	1.3	56
219	Calcipotriene foam, 0.005% in mild-to-moderate plaque psoriasis. Expert Review of Dermatology, 2012, 7, 17-26.	0.3	1
220	The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients. , 0, , .		0
221	Biologics in the treatment of psoriasis and emerging new therapies in the pipeline. Psoriasis: Targets and Therapy, 2012, , 29.	1.2	2
222	Principles of Therapy of Skin Diseases. , 2012, , 2510-2514.		0
223	Disease-syndrome combination clinical study of psoriasis: Present status, advantages, and prospects. Chinese Journal of Integrative Medicine, 2012, 18, 166-171.	0.7	18
224	Application of the dermatology life quality index in clinical trials of biologics for psoriasis. Chinese Journal of Integrative Medicine, 2012, 18, 179-185.	0.7	13
225	Treatment Algorithms for Early Psoriatic Arthritis: Do They Depend on Disease Phenotype?. Current Rheumatology Reports, 2012, 14, 334-342.	2.1	10
226	Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF α treatment. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1444-1448.	1.3	18
227	The evaluation of the clinical effect of topical St Johns wort (<i>Hypericum perforatum</i> L.) in plaque type psoriasis vulgaris: A pilot study. Australasian Journal of Dermatology, 2012, 53, 131-135.	0.4	31
228	The British Association of Dermatologists TM Biologic Interventions Register (BADBIR): design, methodology and objectives. British Journal of Dermatology, 2012, 166, 545-554.	1.4	108
229	Anti-TNF associated psoriasis. Alimentary Pharmacology and Therapeutics, 2012, 35, 308-309.	1.9	1
230	Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochemical Pharmacology, 2012, 83, 1583-1590.	2.0	346

#	ARTICLE	IF	CITATIONS
231	Psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 147-156.	1.4	44
232	Biologics in oral medicine: principles of use and practical considerations. Oral Diseases, 2012, 18, 525-536.	1.5	24
233	Use of anti-tumor necrosis factor- α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan. Journal of Dermatology, 2012, 39, 269-273.	0.6	55
234	Efficacy of additional methotrexate as a maintenance treatment in a Japanese patient with psoriatic arthritis refractory to infliximab monotherapy. Journal of Dermatology, 2012, 39, 954-955.	0.6	2
235	Psoriasis: New insight about pathogenesis, role of barrier organ integrity, NLRP3/CATERPILLER family genes and microbial flora. Journal of Dermatology, 2012, 39, 752-760.	0.6	25
236	Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab ϵ 2 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. British Journal of Dermatology, 2012, 167, 180-190.	1.4	131
237	Patient preferences for psoriasis treatments: impact of treatment experience. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 187-198.	1.3	55
238	Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer Screening Program participants. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 680-685.	1.3	34
239	Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis. Dermatology and Therapy, 2013, 3, 131-142.	1.4	10
240	Sirtuins in dermatology: applications for future research and therapeutics. Archives of Dermatological Research, 2013, 305, 269-282.	1.1	46
241	New era of biologic therapeutics in atopic dermatitis. Expert Opinion on Biological Therapy, 2013, 13, 549-561.	1.4	90
242	Burden of Disease: Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology, 2013, 14, 377-388.	3.3	118
243	Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring. Clinical Reviews in Allergy and Immunology, 2013, 44, 121-140.	2.9	69
244	Might psoriasis be a risk factor for obstructive sleep apnea syndrome?. Sleep and Breathing, 2013, 17, 275-280.	0.9	38
245	Psoriasis, Anti-Tumor Necrosis Factor Therapy, and Tuberculosis: Report of Three Challenging Cases and Literature Review. Infectious Diseases and Therapy, 2013, 2, 59-73.	1.8	10
246	Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents. BioDrugs, 2013, 27, 359-373.	2.2	26
247	Nuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesis. FEBS Letters, 2013, 587, 529-541.	1.3	19
248	Infliximab in Psoriasis and Psoriatic Arthritis. BioDrugs, 2013, 27, 13-23.	2.2	23

#	ARTICLE	IF	CITATIONS
249	Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan. <i>Dermatologica Sinica</i> , 2013, 31, 49-53.	0.2	3
250	Biological therapies for psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1715-1730.	1.4	23
251	Th17 and Th22 cells in psoriatic arthritis and psoriasis. <i>Arthritis Research and Therapy</i> , 2013, 15, R136.	1.6	212
252	Psoriasis as Autoinflammatory Disease. <i>Dermatologic Clinics</i> , 2013, 31, 445-460.	1.0	36
253	Halobetasol propionate 0.05 % cream: a guide to its use in the treatment of plaque psoriasis. <i>Drugs and Therapy Perspectives</i> , 2013, 29, 102-107.	0.3	0
254	Pimecrolimus for psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 767-774.	0.9	5
255	Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1387-1404.	1.3	105
256	Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. <i>Journal of Dermatology</i> , 2013, 40, 55-56.	0.6	16
258	¿Es necesario un calendario de vacunaciones para los pacientes en terapia biológica?. <i>Piel</i> , 2013, 28, 1-4.	0.0	0
259	Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. <i>Actas Dermo-sifiligráficas</i> , 2013, 104, 694-709.	0.2	32
260	Hepatitis C aguda en un paciente en tratamiento con etanercept. <i>Actas Dermo-sifiligráficas</i> , 2013, 104, 239-241.	0.2	3
261	Acute Hepatitis C in a Patient Receiving Etanercept. <i>Actas Dermo-sifiligráficas</i> , 2013, 104, 239-241.	0.2	0
262	Systemic Treatments for Severe Pediatric Psoriasis. <i>Dermatologic Clinics</i> , 2013, 31, 267-288.	1.0	48
263	Psoriasis in the Geriatric Population. <i>Clinics in Geriatric Medicine</i> , 2013, 29, 373-395.	1.0	18
264	Treatment of Psoriasis and Psoriatic Arthritis. <i>BioDrugs</i> , 2013, 27, 3-12.	2.2	42
265	Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. <i>Pharmacoeconomics</i> , 2013, 31, 823-839.	1.7	27
266	The Role of Fcγ ₃ Receptor Polymorphisms in the Response to Anti-“Tumor Necrosis Factor Therapy in Psoriasis. <i>JAMA Dermatology</i> , 2013, 149, 1033.	2.0	38
267	A Review of the Clinical Variants and the Management of Psoriasis. <i>Advances in Skin and Wound Care</i> , 2013, 26, 271-284.	0.5	31

#	ARTICLE	IF	CITATIONS
268	Plaque psoriasis management: a 2013 update. <i>Expert Review of Dermatology</i> , 2013, 8, 229-231.	0.3	0
269	Add-On Effect of Chinese Herbal Medicine Bath to Phototherapy for Psoriasis Vulgaris: A Systematic Review. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-14.	0.5	28
270	Infliximab: Efficacy in psoriasis. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2013, 79, 25.	0.2	7
271	Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. <i>Journal of Dermatological Treatment</i> , 2013, 24, 38-49.	1.1	25
272	Tumor necrosis factor- α antagonists: Side effects and their management. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2013, 79, 35.	0.2	28
273	Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies. <i>Journal of the American Heart Association</i> , 2013, 2, e000062.	1.6	324
274	How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. <i>Journal of Dermatological Treatment</i> , 2013, 24, 13-24.	1.1	28
276	The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. <i>British Journal of Dermatology</i> , 2013, 169, 1295-1303.	1.4	123
277	Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-to-severe psoriasis in Spain. BIOBADADERM registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1366-1374.	1.3	41
278	Japanese guidance for use of biologics for psoriasis (the 2013 version). <i>Journal of Dermatology</i> , 2013, 40, 683-695.	0.6	53
279	Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. <i>Journal of Dermatological Treatment</i> , 2013, 24, 199-208.	1.1	16
280	PSORIASIS: STATE OF THE ART 2013. <i>Acta Clinica Belgica</i> , 2013, 68, 427-432.	0.5	6
281	PSORIASIS: STATE OF THE ART 2013. <i>Acta Clinica Belgica</i> , 2013, 68, 433-441.	0.5	5
282	Rationale and early clinical data on IL-17 blockade in psoriasis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 677-682.	1.3	10
283	Emerging topical treatments for psoriasis. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 523-532.	1.0	17
284	Tumor necrosis factor- α inhibitors and chronic hepatitis C: A comprehensive literature review. <i>World Journal of Gastroenterology</i> , 2013, 19, 7867.	1.4	90
285	Successful Treatment of Plaque Psoriasis with Ustekinumab in a Patient with Chronic Hepatitis B and Latent Tuberculosis. <i>Psoriasis Forum</i> , 2013, 19a, 80-83.	0.1	0
286	Safety of Anti-TNF Alpha Agents in the Pregnant Psoriatic Patient. <i>Current Drug Therapy</i> , 2013, 8, 45-58.	0.2	1

#	ARTICLE	IF	CITATIONS
287	Self-management in patients with psoriasis. <i>Psoriasis: Targets and Therapy</i> , 2014, , 19.	1.2	1
288	Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab. <i>Patient Preference and Adherence</i> , 2014, 8, 865.	0.8	3
289	PsorÃase na infÃncia. <i>Revista Hospital UniversitÃrio Pedro Ernesto</i> , 2014, 13, .	0.1	0
290	Reviewing the Guidelines for Tuberculosis Screening in Psoriasis Patients Treated with Biologics. <i>Psoriasis Forum</i> , 2014, 20a, 163-169.	0.1	0
291	Influence of Cutaneous Involvement in Deciding how to Treat Psoriatic Arthritis. <i>Psoriasis Forum</i> , 2014, 20a, 91-95.	0.1	0
292	Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis. <i>International Journal of Dermatology</i> , 2014, 53, 1531-1535.	0.5	24
293	Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial. <i>Trials</i> , 2014, 15, 495.	0.7	11
294	Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs. <i>Arthritis Research and Therapy</i> , 2014, 16, 420.	1.6	21
295	Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 545-558.	0.7	0
296	Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis. <i>Rheumatology and Therapy</i> , 2014, 1, 1-20.	1.1	23
297	Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 156-169.	0.6	76
298	Relation Between Psoriasis and Geographic Tongue. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2014, 8, ZE06-7.	0.8	8
299	Heterogeneity of Response to Biologic Treatment: Perspective for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 18-23.	0.3	70
300	Severe combined immunodeficiency mouse-psoriatic human skin xenograft model: A modern tool connecting bench to bedside. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2014, 80, 204.	0.2	4
301	Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1117-1124.	1.0	23
302	Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. <i>British Journal of Dermatology</i> , 2014, 170, 366-373.	1.4	48
303	Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective. <i>Value in Health Regional Issues</i> , 2014, 5, 65-72.	0.5	5
304	Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 882-890.	1.3	36

#	ARTICLE	IF	CITATIONS
305	Isoniazid therapy for latent tuberculosis in psoriasis patients receiving biological agents: is it safe and efficacious?. <i>International Journal of Dermatology</i> , 2014, 53, e211-2.	0.5	2
306	Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: A cross-sectional study (Arizona study). <i>Journal of Dermatology</i> , 2014, 41, 673-678.	0.6	57
307	Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). <i>British Journal of Dermatology</i> , 2014, 171, 137-147.	1.4	104
308	Ponesimodene a future oral therapy for psoriasis?. <i>Lancet, The</i> , 2014, 384, 2006-2008.	6.3	10
309	Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 467-478.	3.3	48
310	Biologic fatigue in psoriasis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 78-82.	1.1	65
311	Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. <i>International Journal of Dermatology</i> , 2014, 53, 1305-1318.	0.5	47
312	Efficacy and safety of etanercept in chronic immune-mediated disease. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 649-661.	1.0	24
313	Measuring Psoriasis Severity. <i>Journal of the Dermatology Nurses' Association</i> , 2014, 6, S7-S11.	0.1	1
314	Measuring Psoriasis Severity. <i>Journal of the Dermatology Nurses' Association</i> , 2014, 6, 252-256.	0.1	0
315	Apremilast for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 239-250.	1.3	11
316	Diagnostic difficulties in a patient with generalized pustular psoriasis. <i>Przegląd Dermatologiczny</i> , 2014, 6, 477-480.	0.0	0
317	Diagnosis and Management of Psoriatic Arthritis. <i>Journal of the Dermatology Nurses' Association</i> , 2014, 6, S44-S54.	0.1	0
318	Recommendations for the Coordinated Management of Psoriatic Arthritis by Rheumatologists and Dermatologists: A Delphi Study. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 216-232.	0.2	14
319	From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 178-186.	0.6	61
320	Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. <i>Drugs</i> , 2014, 74, 423-441.	4.9	209
321	Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines. <i>Pharmacoeconomics</i> , 2014, 32, 395-409.	1.7	20
322	Safety and Tolerability of Tumor Necrosis Factor-Î± Inhibitors in Psoriasis: A Narrative Review. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 37-43.	3.3	27

#	ARTICLE	IF	CITATIONS
323	Current Concepts in Psychodermatology. <i>Current Psychiatry Reports</i> , 2014, 16, 449.	2.1	19
324	Research gaps in psoriasis: Opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 146-167.	0.6	101
325	Recent advances in paediatric dermatology. <i>Archives of Disease in Childhood</i> , 2014, 99, 944-948.	1.0	2
326	Comparisons of gene expression in normal, lesional, and non-lesional psoriatic skin using <sc>DNA</sc> microarray techniques. <i>International Journal of Dermatology</i> , 2014, 53, 1213-1220.	0.5	18
327	Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. <i>Rheumatology</i> , 2014, 53, 2100-2109.	0.9	27
328	Genetic markers of treatment response to tumour necrosis factor- α inhibitors in the treatment of psoriasis. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 519-524.	0.6	34
332	Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet, The</i> , 2014, 384, 2036-2045.	6.3	124
334	Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 294.	0.7	10
335	Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1670-1675.	1.3	75
336	Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 790-798.	1.3	25
337	Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases. <i>Drugs</i> , 2014, 74, 1379-1410.	4.9	87
338	Newer agents for psoriasis in adults. <i>BMJ, The</i> , 2014, 349, g4026-g4026.	3.0	5
339	Diagnosing and treating psoriatic arthritis: an update. <i>British Journal of Dermatology</i> , 2014, 170, 772-786.	1.4	28
340	The Role of Interleukin-17A in Psoriatic Disease. <i>BioDrugs</i> , 2014, 28, 487-497.	2.2	37
341	Apremilast: First Global Approval. <i>Drugs</i> , 2014, 74, 825-837.	4.9	52
343	Biologic Therapy with or Without Topical Treatment in Psoriasis: What Does the Current Evidence Say?. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 379-385.	3.3	9
344	Phototherapy, psoriasis, and the age of biologics. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2014, 30, 3-7.	0.7	28
345	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	0.6	423

#	ARTICLE	IF	CITATIONS
346	Treatment of Psoriasis: Focus on Clinic-based Management with Infliximab. American Journal of Clinical Dermatology, 2014, 15, 5-16.	3.3	5
347	The interrelation between a pro-inflammatory milieu and fluorescence diagnosis or photodynamic therapy of human skin cell lines. Photodiagnosis and Photodynamic Therapy, 2014, 11, 91-103.	1.3	10
348	Elaboración mediante el método Delphi de recomendaciones para el manejo coordinado (reumatólogo/dermatólogo) de la artritis psoriásica. Actas Dermo-sifilográficas, 2014, 105, 216-232.	0.2	24
349	Keratin 17: A Critical Player in the Pathogenesis of Psoriasis. Medicinal Research Reviews, 2014, 34, 438-454.	5.0	96
350	Tofacitinib (<sc>CP</sc>â€690,550), an oral Janus kinase inhibitor, improves patientâ€reported outcomes in a phase 2b, randomized, doubleâ€blind, placeboâ€controlled study in patients with moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 192-203.	1.3	59
351	Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil. BMJ Open, 2014, 4, e004179.	0.8	10
352	New and emerging biologic therapies for moderateâ€toâ€severe plaque psoriasis: mechanistic rationales and recent clinical data for<sc>IL</sc>â€17 and<sc>IL</sc>â€23 inhibitors. Dermatologic Therapy, 2015, 28, 179-193.	0.8	49
353	Physicianâ€based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2002-2010.	1.3	139
354	Realâ€life effectiveness of onceâ€daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52â€week <sc>PRO</sc>â€long study. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2349-2355.	1.3	33
355	Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. International Journal of Clinical Rheumatology, 2015, 10, 451-459.	0.3	11
356	Pictorial representation of illness and self measure (<sc>PRISM</sc>): an effective tool to assess the burden of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2356-2362.	1.3	18
357	Effect of Pregnancy on Psoriasis and Psoriatic Arthritis. Psoriasis Forum, 2015, 21a, 12-27.	0.1	0
358	Analysis of Gender Differences in the Efficacy of Psoriasis Treatment Modalities Resulting in Clearance. Psoriasis Forum, 2015, 21a, 28-34.	0.1	1
359	Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review. Psoriasis: Targets and Therapy, 2015, 5, 71.	1.2	5
360	Efficacy and Safety of Tripterygium wilfordii Hook F Versus Acitretin in Moderate to Severe Psoriasis Vulgaris. Chinese Medical Journal, 2015, 128, 443-449.	0.9	58
361	Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece. ClinicoEconomics and Outcomes Research, 2015, 7, 73.	0.7	2
362	Use of tumor necrosis factor alpha (TNF Î±) antagonists in a patient with psoriasis and Chagas disease. Anais Brasileiros De Dermatologia, 2015, 90, 171-174.	0.5	6
363	A Review of Annular Eruptions in Children. Pediatric Annals, 2015, 44, e199-204.	0.3	2

#	ARTICLE	IF	CITATIONS
364	Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment. PLoS ONE, 2015, 10, e0129120.	1.1	51
365	Bone-Immune Cell Crosstalk: Bone Diseases. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	60
366	A Clinician's Guide to Diagnosing and Managing Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2015, 1, 9-25.	0.3	0
367	Pharmacological Properties of Monoclonal Antibodies Directed Against Interleukins. , 2015, , .		3
368	Combination therapy of cyclosporine and anti-tumor necrosis factor $\hat{\pm}$ in psoriasis: a case series of 10 patients. Dermatologic Therapy, 2015, 28, 126-130.	0.8	13
369	Expert Recommendations on Treating Psoriasis in Special Circumstances. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 292-309.	0.2	1
370	Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2015, 42, 479-488.	1.0	122
371	Mesoporous Nano-carbon particle Loaded Fisetin has a Positive Therapeutic Effect in a Murine Preclinical Model of Ovalbumin Induced Acute Allergic Asthma. Journal of Nanomedicine & Biotherapeutic Discovery, 2015, 05, .	0.6	1
372	The 5-point Investigatorâ€™s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. Journal of Dermatological Treatment, 2015, 26, 23-31.	1.1	173
373	Comparison of infliximab and ustekinumab for the treatment of moderate-to-severe psoriasis: an indirect comparison meta-analysis. Comparative Effectiveness Research, 2015, , 1.	0.2	1
375	EstimaciÃ³n de la prevalencia de infecciÃ³n tuberculosa latente en pacientes con psoriasis en placas moderada a grave en EspaÃ±a. Estudio Latent. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 823-829.	0.2	2
376	Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies. Clinical Investigation, 2015, 5, 777-791.	0.0	1
377	Essential Role of microRNA in Skin Physiology and Disease. Advances in Experimental Medicine and Biology, 2015, 888, 307-330.	0.8	8
378	Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain. European Journal of Dermatology, 2015, 25, 410-417.	0.3	3
379	Estimation of the prevalence of latent tuberculosis infection in patients with moderate to severe plaque psoriasis in Spain: The Latent study. Actas Dermo-sifiliogrÃ¡ficas, 2015, 106, 823-829.	0.2	0
380	Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis. Chinese Medicine, 2015, 10, 27.	1.6	17
381	Hidradenitis Suppurativa Management in the United States: An Analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases. Skin Appendage Disorders, 2015, 1, 65-73.	0.5	24
382	Treatment patterns with topicals, traditional systemics and biologics in psoriasis â€” a Swedish database analysis. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 215-223.	1.3	33

#	ARTICLE	IF	CITATIONS
383	Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales. Actas Dermo-sifilograficas, 2015, 106, 292-309.	0.2	9
384	Impact of a Performance Improvement CME activity on the care and treatment of patients with psoriasis. Journal of the American Academy of Dermatology, 2015, 72, 516-523.	0.6	15
385	Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg?. Hepatology, 2015, 61, 703-711.	3.6	192
386	Infection risk associated with anti-TNF- α agents: a review. Expert Opinion on Drug Safety, 2015, 14, 571-582.	1.0	153
387	Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. British Journal of Dermatology, 2015, 172, 230-238.	1.4	20
388	Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1063-1070.	1.3	81
389	Epigenetic Mechanisms of Sirtuins in Dermatology. , 2015, , 137-175.		1
390	Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate in Patients with Psoriasis Vulgaris. Clinical Drug Investigation, 2015, 35, 239-245.	1.1	39
391	Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan. Dermatologica Sinica, 2015, 33, 119-123.	0.2	6
392	Psoriasis: classical and emerging comorbidities. Anais Brasileiros De Dermatologia, 2015, 90, 9-20.	0.5	266
393	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 73, 37-49.	0.6	498
394	To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2015, 73, 420-428.e1.	0.6	32
395	Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. Journal of Investigative Dermatology, 2015, 135, 2955-2963.	0.3	107
396	Dissatisfaction with cutaneous body image is directly correlated with insomnia severity: A prospective study in a non-clinical sample. Journal of Dermatological Treatment, 2015, 26, 193-197.	1.1	18
397	Treatment Satisfaction of Patients with Psoriasis. Acta Dermato-Venereologica, 2015, 95, 572-578.	0.6	48
398	Increased risk of arrhythmia in patients with psoriatic disease: A nationwide population-based matched cohort study. Journal of the American Academy of Dermatology, 2015, 73, 429-438.	0.6	43
399	Psoriasis patients TM willingness to accept side-effect risks for improved treatment efficacy. Journal of Dermatological Treatment, 2015, 26, 507-513.	1.1	22
400	The inhibitory mechanism by curcumin on the Zac1-enhanced cyclin D1 expression in human keratinocytes. Journal of Dermatological Science, 2015, 79, 262-267.	1.0	3

#	ARTICLE	IF	CITATIONS
401	The Antipsoriatic Agent Monomethylfumurate Has Antiproliferative, Prodifferentiative, and Anti-Inflammatory Effects on Keratinocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 90-97.	1.3	23
402	Effective Strategies for the Management of Pyoderma Gangrenosum: A Comprehensive Review. <i>Acta Dermato-Venereologica</i> , 2015, 95, 525-531.	0.6	95
403	Psoriasis during pregnancy: characteristics and important management recommendations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 709-720.	1.3	28
404	Nanostructures of an amphiphilic zinc phthalocyanine polymer conjugate for photodynamic therapy of psoriasis. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 128, 405-409.	2.5	47
405	Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor- α inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 741-743.	0.6	3
406	The Relationship of Obesity With the Severity of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 450-456.	0.6	68
407	Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis. <i>JAMA Dermatology</i> , 2015, 151, 961.	2.0	308
408	Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 116-124.e7.	1.5	225
409	Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. <i>International Journal of Obesity</i> , 2015, 39, 1197-1202.	1.6	87
410	The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. <i>Journal of Dermatological Treatment</i> , 2015, 26, 19-22.	1.1	31
411	A guide to prescribing home phototherapy for patients with psoriasis: The appropriate patient, the type of unit, the treatment regimen, and the potential obstacles. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 868-878.e1.	0.6	32
412	Screening and Vaccinations in Patients Requiring Systemic Immunosuppression: An Update for Dermatologists. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 179-195.	3.3	11
413	Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting. <i>Journal of Dermatological Treatment</i> , 2015, 26, 217-222.	1.1	13
414	Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 623-642.	0.8	50
415	Effects of Curcuma extract and visible light on adults with plaque psoriasis. <i>European Journal of Dermatology</i> , 2015, 25, 240-246.	0.3	31
416	Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial. <i>BMC Dermatology</i> , 2015, 15, 9.	2.1	6
417	Acupuncture Therapies for Psoriasis Vulgaris: A Systematic Review of Randomized Controlled Trials. <i>Complementary Medicine Research</i> , 2015, 22, 102-109.	0.5	10
418	CXCL10 in psoriasis. <i>Advances in Medical Sciences</i> , 2015, 60, 349-354.	0.9	48

#	ARTICLE	IF	CITATIONS
419	An overview of developing TNF- α targeted therapy for the treatment of psoriasis. Expert Opinion on Investigational Drugs, 2015, 24, 1343-1354.	1.9	27
420	Reply to: "Comment on "Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor- α inhibitors" Journal of the American Academy of Dermatology, 2015, 73, e125-e126.	0.6	3
421	Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. Journal of the American Academy of Dermatology, 2015, 73, 585-593.e3.	0.6	47
422	Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis. Journal of Cutaneous Medicine and Surgery, 2015, 19, 361-366.	0.6	7
423	Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 955-963.	1.3	81
424	Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients with Comorbid Psoriatic Arthritis. Arthritis Care and Research, 2015, 67, 708-717.	1.5	53
425	Association of chronic periodontitis and psoriasis: periodontal status with severity of psoriasis. Oral Diseases, 2015, 21, 314-319.	1.5	39
426	Ten Years On. Dermatologic Clinics, 2015, 33, 111-125.	1.0	18
427	The International Psoriasis Council: Advancing Knowledge, Enhancing Care. Dermatologic Clinics, 2015, 33, ix-xii.	1.0	1
428	Periostin contributes to epidermal hyperplasia in psoriasis common to atopic dermatitis. Allergology International, 2015, 64, 41-48.	1.4	41
429	Erythrodermic psoriasis treated with apremilast. Dermatology Reports, 2016, 8, 6599.	0.4	10
431	Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World Journal of Gastroenterology, 2016, 22, 6444.	1.4	39
432	Haptoglobin protein and mRNA expression in psoriasis and its clinical significance. Molecular Medicine Reports, 2016, 14, 3735-3742.	1.1	5
433	Management of scalp psoriasis: current perspectives. Psoriasis: Targets and Therapy, 2016, 6, 33.	1.2	12
434	Assessment and monitoring of biologic drug adverse events in patients with psoriasis. Psoriasis: Targets and Therapy, 2016, 6, 41.	1.2	3
436	Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 396-405.	0.5	18
437	Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity. Mediators of Inflammation, 2016, 2016, 1-8.	1.4	6
438	Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts. Current Drug Safety, 2016, 11, 35-43.	0.3	24

#	ARTICLE	IF	CITATIONS
439	Apremilast. , 2016, , 75-82.		0
441	Quantitative and simultaneous non-invasive measurement of skin hydration and sebum levels. Biomedical Optics Express, 2016, 7, 2311.	1.5	30
442	Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Preference and Adherence, 2016, Volume 10, 2357-2367.	0.8	79
444	Current knowledge on psoriasis and autoimmune diseases. Psoriasis: Targets and Therapy, 2016, 6, 7.	1.2	122
446	Economic Burden of Psoriasis and Potential Cost Offsets with Biologic Treatment: A Swedish Register Analysis. Acta Dermato-Venereologica, 2016, 96, 651-657.	0.6	15
447	Serum level of receptor activator of nuclear factor kappa β ligand in patients with psoriasis. International Journal of Dermatology, 2016, 55, e227-33.	0.5	9
448	Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). Journal of Controlled Release, 2016, 239, 182-202.	4.8	77
449	Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1121-1128.	1.5	14
450	Infrared spectroscopic measurement of skin hydration and sebum levels and comparison to corneometer and sebumeter. Proceedings of SPIE, 2016, , .	0.8	2
451	Screening of Patients with Psoriasis for Psoriatic Arthritis in the Slovak Republic. Acta Medica Martiniana, 2016, 16, 32-42.	0.4	4
452	Serbian Association of Dermatovenereologists TM Guidelines for the Diagnosis and Treatment of Psoriasis. Serbian Journal of Dermatology and Venereology, 2016, 8, 61-78.	0.2	1
454	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Annals of the Rheumatic Diseases, 2016, 75, 1065-1073.	0.5	225
455	â€žDrugâ€™Survivalâ€™Raten und GrÃ¼nde fÃ¼r den Abbruch von Systemtherapien bei Psoriasis. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1090-1101.	0.4	2
456	Major Depression and Psoriasis: A Psychodermatological Phenomenon. Skin Pharmacology and Physiology, 2016, 29, 220-230.	1.1	43
457	Cost-Effectiveness Analysis of Ixekizumab vs. Secukinumab in Sequential Biologic Treatment of Psoriasis in the UK. Value in Health, 2016, 19, A568.	0.1	0
458	Predicting disease-microbe association by random walking on the heterogeneous network. , 2016, , .		11
459	Psoriasis. Clinics in Podiatric Medicine and Surgery, 2016, 33, 355-366.	0.2	52
460	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 83-98.e4.	0.6	264

#	ARTICLE	IF	CITATIONS
461	Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence. Seminars in Cutaneous Medicine and Surgery, 2016, 35, S36-S44.	1.6	41
462	Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Expert Review of Clinical Pharmacology, 2016, 9, 789-797.	1.3	9
463	Methods for Evaluating Clinical Evidence. Evidence-based Clinical Chinese Medicine, 2016, , 33-43.	0.0	0
464	Itch Management: Physical Approaches (UV Phototherapy, Acupuncture). Current Problems in Dermatology, 2016, 50, 54-63.	0.8	8
465	Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients. Dermatology and Therapy, 2016, 6, 413-425.	1.4	64
466	Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. Journal of the American Academy of Dermatology, 2016, 75, 1156-1161.	0.6	39
467	Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. Acta Dermato-Venereologica, 2016, 96, 23-28.	0.6	39
468	A statistical analysis plan for the efficiency and safety of Chinese herbal medicine used concurrently with topical therapy for psoriasis vulgaris. Trials, 2016, 17, 482.	0.7	2
469	Calcipotriol/Betamethasone Dipropionate Foam: A Review in Plaque Psoriasis. Drugs, 2016, 76, 1485-1492.	4.9	14
470	Topical treatments for scalp psoriasis: evidence-based guide. The Prescriber, 2016, 27, 38-41.	0.1	1
471	Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2016, 175, 157-162.	1.4	81
472	Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1957-1960.	1.3	37
473	<sc>TUR</sc>-<sc>PSO</sc>: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey. Journal of Dermatology, 2016, 43, 298-304.	0.6	13
474	A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. Journal of Rheumatology, 2016, 43, 1724-1734.	1.0	175
475	Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes. JAMA Dermatology, 2016, 152, 1244.	2.0	56
476	A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50Âmg twice weekly followed by etanercept 25Âmg twice weekly, the combination of etanercept 25Âmg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. BMC Dermatology, 2016, 16, 11.	2.1	21
477	Psoriasis. Nature Reviews Disease Primers, 2016, 2, 16082.	18.1	585
478	Drug survival rates and reasons for drug discontinuation in psoriasis. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1089-1099.	0.4	57

#	ARTICLE	IF	CITATIONS
479	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor. <i>Journal of the American Association of Nurse Practitioners</i> , 2016, 28, 683-695.	0.5	9
480	Ultraviolet B radiation therapy for psoriasis: Pursuing the optimal regime. <i>Clinics in Dermatology</i> , 2016, 34, 587-593.	0.8	24
481	Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications. <i>CNS Drugs</i> , 2016, 30, 1149-1168.	2.7	3
482	Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. <i>BMJ Open</i> , 2016, 6, e011941.	0.8	10
483	Reliability and validity of the Arabic version of the Psoriasis Disability Index questionnaire. <i>Journal of the Egyptian Women's Dermatologic Society</i> , 2016, 13, 143-150.	0.2	4
484	Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 567-575.	1.0	17
485	Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 923-935.	1.5	17
486	Cryosurgery for Psoriasis. , 2016, , 557-561.		0
487	Current status and future prospects for biologic treatments of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1273-1287.	1.3	19
488	Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. <i>Dermatology and Therapy</i> , 2016, 6, 151-167.	1.4	10
489	Los 10 diagn3sticos m3s frecuentes en dermatolog3a. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2016, 23, 119-141.	0.0	0
490	SnapshotDx Quiz: January 2016. <i>Journal of Investigative Dermatology</i> , 2016, 136, e9-e10.	0.3	0
491	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 291-304.	1.6	119
492	Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial. <i>Trials</i> , 2016, 17, 140.	0.7	18
493	Tofacitinib for the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1421-1433.	0.9	20
494	The role of specialty pharmacy drugs in the management of inflammatory diseases. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 821-830.	0.5	16
495	Translating psoriasis guidelines into practice: Important gaps revealed. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 544-551.	0.6	7
496	Relevant Laboratory Tests and Therapeutic Monitoring in Psoriasis. , 2016, , 221-226.		0

#	ARTICLE	IF	CITATIONS
497	Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 141, 141-147.	2.5	104
498	Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis. <i>Annals of Pharmacotherapy</i> , 2016, 50, 341-351.	0.9	25
499	Apremilast. <i>Annals of Pharmacotherapy</i> , 2016, 50, 282-290.	0.9	17
500	Managing Patients With Psoriasis in the Busy Clinic. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 196-206.	0.6	16
501	Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study. <i>Journal of Dermatological Treatment</i> , 2016, 27, 339-345.	1.1	2
502	Terms referring to psoriasis vulgaris in the classical Chinese medicine literature: a systematic analysis. <i>Complementary Therapies in Medicine</i> , 2016, 25, 55-60.	1.3	14
503	Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study. <i>Journal of Dermatological Treatment</i> , 2016, 27, 120-127.	1.1	94
504	Ultraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 125-133.	3.3	46
505	Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 525-539.	1.3	2
506	Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 79-86.	3.3	21
507	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 87-97.	3.3	173
508	Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. <i>Journal of Alternative and Complementary Medicine</i> , 2016, 22, 174-188.	2.1	19
509	Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who are Candidates for Biologic Therapy. <i>Journal of the Dermatology Nurses' Association</i> , 2018, 10, 120-132.	0.1	8
510	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2016, 152, 661.	2.0	46
511	Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1057-1065.e4.	0.6	102
512	Anti-interleukin-17 treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 311-315.	1.1	12
513	Candidate gene polymorphisms and risk of psoriasis: A pilot study. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 1217-1222.	0.8	28
514	Patient-relevant treatment goals in psoriasis. <i>Archives of Dermatological Research</i> , 2016, 308, 69-78.	1.1	92

#	ARTICLE	IF	CITATIONS
515	A systematic review on the efficacy and safety of Infliximab in patients with psoriasis. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 431-437.	1.4	5
516	Psoriatic Arthritis and Psoriasis. , 2016, , .		3
517	A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 237-249.	1.3	41
518	Reactivation of Hepatitis B Virus Due to Cancer Chemotherapy and Other Immunosuppressive Drug Therapy. <i>Molecular and Translational Medicine</i> , 2016, , 399-431.	0.4	0
519	Novel systemic therapies for the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 79-92.	0.9	18
520	Secukinumab for treating plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 119-128.	1.4	18
521	Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. <i>Journal of Dermatological Treatment</i> , 2016, 27, 203-209.	1.1	15
522	Erythrodermic psoriasis and severe hypotension requiring intensive care unit hospitalization: Poor treatment outcome as a result of poor adherence. <i>Journal of Dermatological Treatment</i> , 2016, 27, 134-135.	1.1	3
523	Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. <i>Clinical Pharmacokinetics</i> , 2016, 55, 297-311.	1.6	44
524	A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 19-26.	1.1	61
525	Influence of oxidative injury and monitoring of blood plasma by DSC on patients with psoriasis. <i>Journal of Thermal Analysis and Calorimetry</i> , 2016, 123, 2037-2043.	2.0	15
526	A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 864-865.	1.3	27
527	Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region. <i>Journal of Dermatological Treatment</i> , 2017, 28, 129-135.	1.1	5
528	Psoriasis and the liver: problems, causes and course. <i>Australasian Journal of Dermatology</i> , 2017, 58, 194-199.	0.4	14
529	Is psoriasis an autoimmune disease? Interpretations from an immunofluorescence-based study. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 346-351.	0.7	7
530	microRNA-130a Promotes Human Keratinocyte Viability and Migration and Inhibits Apoptosis Through Direct Regulation of STK40-Mediated NF- κ B Pathway and Indirect Regulation of SOX9-Mediated JNK/MAPK Pathway: A Potential Role in Psoriasis. <i>DNA and Cell Biology</i> , 2017, 36, 219-226.	0.9	19
531	Psoriasis and comorbid diseases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 393-403.	0.6	152
532	Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 189-200.	0.4	7

#	ARTICLE	IF	CITATIONS
533	Vascular Inflammation Imaging in Psoriasis. <i>Current Cardiovascular Imaging Reports</i> , 2017, 10, 1.	0.4	2
534	Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2017, 37, 439-451.	1.1	35
535	Apremilast: A Review in Psoriasis and Psoriatic Arthritis. <i>Drugs</i> , 2017, 77, 459-472.	4.9	140
536	Psoriasis for the primary care practitioner. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 157-178.	0.5	17
537	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 405-411.	3.3	24
538	Apremilast for the management of moderate to severe plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 349-360.	1.3	19
539	Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1271-1284.	1.3	21
540	Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 88-97.e5.	0.6	82
541	Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 965-971.	0.8	31
542	Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data. <i>Dermatology and Therapy</i> , 2017, 7, 97-109.	1.4	53
543	Psoriasis & psoriatic therapies. <i>Nurse Practitioner</i> , 2017, 42, 35-39.	0.2	2
544	Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. <i>Journal of Medical Economics</i> , 2017, 20, 982-990.	1.0	33
545	Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. <i>Journal of Medical Economics</i> , 2017, 20, 1000-1006.	1.0	7
546	Taiwanese Dermatological Association consensus statement on management of psoriasis. <i>Dermatologica Sinica</i> , 2017, 35, 66-77.	0.2	27
547	Development of medicated foams that combine incompatible hydrophilic and lipophilic drugs for psoriasis treatment. <i>International Journal of Pharmaceutics</i> , 2017, 524, 65-76.	2.6	11
548	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1093-1102.	0.6	110
549	Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER2 and UNCOVER3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1483-1490.	1.3	33
550	Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. <i>Clinical Drug Investigation</i> , 2017, 37, 493-501.	1.1	15

#	ARTICLE	IF	CITATIONS
551	Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 322-330.	1.3	11
552	Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis. <i>Clinical Drug Investigation</i> , 2017, 37, 355-361.	1.1	9
553	Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 115-121.	0.9	16
554	MicroRNA138 regulates keratin 17 protein expression to affect HaCaT cell proliferation and apoptosis by targeting hTERT in psoriasis vulgaris. <i>Biomedicine and Pharmacotherapy</i> , 2017, 85, 169-176.	2.5	16
555	Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1510-1518.	1.5	102
556	Calcipotriol Inhibits Proliferation of Human Keratinocytes by Downregulating Stat1 and Stat3 Signaling. <i>Journal of Investigative Medicine</i> , 2017, 65, 376-381.	0.7	10
557	Comparison of psoriasis and atopic dermatitis guidelinesâ€”an argument for aggressive atopic dermatitis management. <i>Pediatric Dermatology</i> , 2017, 34, 739-742.	0.5	5
558	Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2247-2259.	1.4	87
560	Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1038-1046.	0.6	38
561	Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature. <i>Therapeutic Delivery</i> , 2017, 8, 737-746.	1.2	17
562	Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1999-2009.	1.3	150
563	Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 716-721.	1.1	22
564	Cyclosporine in the Treatment of Psoriasis. <i>Journal of the Dermatology Nurses' Association</i> , 2017, 9, 98-101.	0.1	2
565	Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1562-1574.	1.4	68
566	Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. <i>Drugs and Aging</i> , 2017, 34, 583-588.	1.3	10
567	Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. <i>Journal of Medical Economics</i> , 2017, 20, 1224-1230.	1.0	23
568	Apremilast in psoriasis: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 361-367.	0.3	1
569	An Assessment of the Continuing Education Needs of Nurse Practitioners Who Manage Patients With Psoriasis. <i>Journal of the Dermatology Nurses' Association</i> , 2017, 9, 131-135.	0.1	1

#	ARTICLE	IF	CITATIONS
570	Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. <i>Journal of Dermatological Treatment</i> , 2017, 28, 623-630.	1.1	16
571	Rate of serious infection in patients who are prescribed systemic biologic or nonbiologic agents for psoriasis: A large, single center, retrospective, observational cohort study. <i>Dermatologic Therapy</i> , 2017, 30, e12529.	0.8	9
572	BehandlungsprÄferenzen fÄ¼r Biologika bei Psoriasis: erfahrene Patienten legen Wert auf Nachhaltigkeit. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 189-201.	0.4	12
573	Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis. <i>Dermatology and Therapy</i> , 2017, 7, 463-483.	1.4	28
574	Patientsâ€™ Perspectives on the Impact of Genital Psoriasis: A Qualitative Study. <i>Dermatology and Therapy</i> , 2017, 7, 447-461.	1.4	39
575	DFD-01 Reduces Transepidermal Water Loss and Improves Skin Hydration and Flexibility. <i>Dermatology and Therapy</i> , 2017, 7, 507-514.	1.4	2
576	Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants. <i>BioDrugs</i> , 2017, 31, 545-554.	2.2	34
577	Bioactive Polyphenols for Diabetes and Inflammation in Psoriasis Disease. <i>Studies in Natural Products Chemistry</i> , 2017, , 231-268.	0.8	7
578	Update on Ustekinumab for Psoriasis. <i>Current Dermatology Reports</i> , 2017, 6, 29-34.	1.1	0
579	The role of IL-23 and the IL-23/Th17 immune axis in the pathogenesis and treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1616-1626.	1.3	187
580	Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. <i>Arthritis Research and Therapy</i> , 2017, 19, 72.	1.6	64
581	Prioritizing disease-causing microbes based on random walking on the heterogeneous network. <i>Methods</i> , 2017, 124, 120-125.	1.9	14
582	Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2017, 33, 279-287.	0.9	40
583	Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). <i>Journal of Dermatological Treatment</i> , 2017, 28, 394-400.	1.1	11
584	Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. <i>Journal of Autoimmunity</i> , 2017, 76, 21-37.	3.0	94
585	Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Drugs in R and D</i> , 2017, 17, 29-51.	1.1	33
586	A novel electromechanical autoinjector, AutoTouchâ„¢, for self-injection of etanercept: real-world use and benefits. <i>Postgraduate Medicine</i> , 2017, 129, 118-125.	0.9	14
587	Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2017, 28, 374-383.	1.1	35

#	ARTICLE	IF	CITATIONS
588	Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. <i>Journal of Dermatological Treatment</i> , 2017, 28, 290-298.	1.1	6
589	Efficiency and safety of a <i>Curcuma</i> extract combined with visible blue light phototherapy on adults with plaque psoriasis: A phase IV, randomized, open pilot clinical trial. <i>Journal of Dermatology</i> , 2017, 44, 1177-1178.	0.6	4
590	Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. <i>Journal of Dermatological Treatment</i> , 2017, 28, 390-393.	1.1	7
591	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSOABLE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 119-126.	1.3	92
592	Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris. <i>Journal of Dermatological Treatment</i> , 2017, 28, 213-220.	1.1	12
593	The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 798-807.	1.3	103
594	MicroRNA-520a suppresses the proliferation and mitosis of HaCaT cells by inactivating protein kinase B. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 6207-6212.	0.8	6
595	Patient Satisfaction Scores and Standard of Care Compliance in Patients on Biologic Therapy for Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 102-105.	0.3	0
596	Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions. <i>Dermatology</i> , 2017, 233, 425-434.	0.9	31
597	Custom-made micro applicators for high-dose-rate brachytherapy treatment of chronic psoriasis. <i>Journal of Contemporary Brachytherapy</i> , 2017, 3, 263-269.	0.4	6
599	Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity. <i>Frontiers in Endocrinology</i> , 2017, 8, 139.	1.5	22
600	Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2017, 2017, 1-13.	1.4	32
601	Contribution of <i>In Vivo</i> and Organotypic 3D Models to Understanding the Role of Macrophages and Neutrophils in the Pathogenesis of Psoriasis. <i>Mediators of Inflammation</i> , 2017, 2017, 1-13.	1.4	23
602	Effects of Wannachawee Recipe with Antipsoriatic Activity on Suppressing Inflammatory Cytokine Production in HaCaT Human Keratinocytes. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-12.	0.5	12
603	Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0179447.	1.1	28
604	BETAMETHASONE DIPROPIONATE GEL FOR TREATMENT OF LOCALIZED PLAQUE PSORIASIS. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2017, 9, 173.	0.3	14
605	Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 370-381.	0.5	16
606	Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 181-188.	0.7	4

#	ARTICLE	IF	CITATIONS
607	Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab. <i>Acta Dermato-Venereologica</i> , 2017, 97, 705-710.	0.6	10
608	Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 661-669.	0.8	27
609	Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 353-362.	0.8	17
610	Astilbin emulsion improves guinea pig lesions in a psoriasis-like model by suppressing IL-6 and IL-22 via p38 MAPK. <i>Molecular Medicine Reports</i> , 2018, 17, 3789-3796.	1.1	11
611	Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis. <i>Current Dermatology Reports</i> , 2018, 7, 37-42.	1.1	4
612	The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor inhibitors versus phototherapy: An observational cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 60-68.	0.6	54
613	Evaluation of the effect of pulsed dye laser on chronic psoriatic plaque. <i>Journal of Dermatological Treatment</i> , 2018, 29, 786-791.	1.1	3
614	Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. <i>Journal of Dermatological Treatment</i> , 2018, 29, 769-774.	1.1	29
615	Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. <i>Current Medical Research and Opinion</i> , 2018, 34, 1325-1333.	0.9	27
616	Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach. <i>Rheumatology and Therapy</i> , 2018, 5, 87-98.	1.1	1
617	Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations. <i>Current Dermatology Reports</i> , 2018, 7, 59-74.	1.1	6
618	Comparative analysis of Lacistema pubescens and dexamethasone on topical treatment of skin inflammation in a chronic disease model and side effects. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 576-582.	1.2	9
619	Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. <i>Archives of Dermatological Research</i> , 2018, 310, 271-319.	1.1	84
620	The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. <i>Journal of Medical Economics</i> , 2018, 21, 537-541.	1.0	3
621	Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 586-592.	1.1	7
622	Safety of biologic agents for psoriasis in patients with viral hepatitis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 553-556.	1.1	11
623	Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 5-21.	1.1	121
624	A brief look at the role of monocyte chemoattractant protein-1 (CCL2) in the pathophysiology of psoriasis. <i>Cytokine</i> , 2018, 110, 226-231.	1.4	53

#	ARTICLE	IF	CITATIONS
625	The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 557-568.	1.1	35
626	Sleep Deficiency and Psoriasis: Implications for Clinical Practice. <i>Journal for Nurse Practitioners</i> , 2018, 14, 389-395.	0.4	0
627	Itching for answers: Prevalence and severity of pruritus in psoriasis. <i>Australasian Journal of Dermatology</i> , 2018, 59, 206-209.	0.4	17
628	Systemic Therapies in Psoriasis. , 2018, , 145-158.		0
629	Drug survival of biologic therapies for the treatment of psoriasis: Results of Slovenian national registry. <i>Biologics</i> , 2018, 54, 44-49.	0.5	11
630	Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. <i>Journal of Medical Economics</i> , 2018, 21, 745-754.	1.0	10
631	Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?. <i>Experimental Dermatology</i> , 2018, 27, 737-747.	1.4	22
632	Successful Treatment of Inflammatory Linear Verrucous Epidermal Nevus with Concomitant Psoriasis Using Etanercept. <i>Case Reports in Dermatology</i> , 2018, 10, 29-34.	0.3	4
633	Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 561-575.	0.9	31
634	MALDI imaging facilitates new topical drug development process by determining quantitative skin distribution profiles. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 2815-2828.	1.9	51
635	A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. <i>Experimental Dermatology</i> , 2018, 27, 22-29.	1.4	46
636	Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US drug launches. <i>Current Medical Research and Opinion</i> , 2018, 34, 765-773.	0.9	10
637	Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan. <i>Journal of Dermatological Treatment</i> , 2018, 29, 24-31.	1.1	10
638	The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 404-412.	0.8	6
639	Review of IL-17 inhibitors for psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 347-352.	1.1	21
640	PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 481-486.	1.1	15
641	A clinical review of phototherapy for psoriasis. <i>Lasers in Medical Science</i> , 2018, 33, 173-180.	1.0	174
642	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 741-748.	0.6	22

#	ARTICLE	IF	CITATIONS
643	Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 1-13.	3.3	56
644	Drug survival of biologic treatments in psoriasis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 460-466.	1.1	66
645	Psoriasis in the mature patient: Therapeutic approach in the era of biologics. <i>Clinics in Dermatology</i> , 2018, 36, 222-230.	0.8	13
646	Identifying Psoriasis and Psoriatic Arthritis Patients in Retrospective Databases When Diagnosis Codes Are Not Available: A Validation Study Comparing Medication/Prescriber Visit-Based Algorithms with Diagnosis Codes. <i>Value in Health</i> , 2018, 21, 110-116.	0.1	8
647	Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey. <i>Dermatologic Therapy</i> , 2018, 31, e12565.	0.8	4
648	Pathogenesis of psoriasis and development of treatment. <i>Journal of Dermatology</i> , 2018, 45, 264-272.	0.6	309
649	The association of ERAP1 and ERAP2 single nucleotide polymorphisms and their haplotypes with psoriasis vulgaris is dependent on the presence or absence of the HLA-C*06:02 allele and age at disease onset. <i>Human Immunology</i> , 2018, 79, 109-116.	1.2	30
650	A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 467-474.	1.1	6
651	A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 135-148.	1.4	18
652	Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 355-362.	1.3	25
653	Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. <i>Annals of Pharmacotherapy</i> , 2018, 52, 380-387.	0.9	9
654	Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. <i>Journal of Dermatological Treatment</i> , 2018, 29, 220-229.	1.1	14
655	Epidemiology of psoriasis in the years 2008-2015 in Poland. <i>Przegląd Dermatologiczny</i> , 2018, 105, 693-700.	0.0	5
656	Association of ERAP1 gene polymorphisms with the susceptibility to psoriasis vulgaris. <i>Medicine (United States)</i> , 2018, 97, e12828.	0.4	9
657	Effects of aloe polysaccharide, a polysaccharide extracted from <i>Aloe vera</i> , on TNF α -induced HaCaT cell proliferation and the underlying mechanism in psoriasis. <i>Molecular Medicine Reports</i> , 2018, 18, 3537-3543.	1.1	15
658	Effects of Weight Loss on Psoriasis: A Review of Clinical Trials. <i>Cureus</i> , 2018, 10, e3491.	0.2	23
659	Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1210-1217.	0.5	21
660	Guselkumab: A Review in Moderate to Severe Plaque Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 907-918.	3.3	25

#	ARTICLE	IF	CITATIONS
661	Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology, 2018, 11, 1209-1218.	1.3	18
662	The Cost of Psoriasis in Patients under Conventional Systemic Therapy or Biologic: The Results of a Retrospective Analysis Carried out in an Italian Center. Journal of Clinical & Experimental Dermatology Research, 2018, 09, .	0.1	0
663	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. Cell Reports, 2018, 25, 3564-3572.e4.	2.9	49
664	Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 747-759.	0.7	6
665	Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis. Experimental and Therapeutic Medicine, 2018, 16, 5085-5095.	0.8	16
666	Impact of Metalloproteinase 1 Deficiency Induced by Specific Small Hairpin RNA on the Physiological Effects of Tumor Necrosis Factor. Russian Journal of Genetics, 2018, 54, 960-966.	0.2	0
667	MicroRNAs as biological regulators in skin disorders. Biomedicine and Pharmacotherapy, 2018, 108, 996-1004.	2.5	58
668	Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clinical, Cosmetic and Investigational Dermatology, 2018, Volume 11, 451-459.	0.8	10
669	Association of Psoriasis With Inflammatory Bowel Disease. JAMA Dermatology, 2018, 154, 1417.	2.0	174
670	Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study. Journal of the American Academy of Dermatology, 2018, 79, 1061-1068.e1.	0.6	26
671	The Amelioration Effect of the Ethanolic Extract of Cnidium officinale in Mice with Imiquimod-induced Psoriasis-like Skin Lesion. Natural Product Sciences, 2018, 24, 21.	0.2	2
672	Patients'™ and Physicians'™ Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare). Acta Dermato-Venereologica, 2018, 98, 200-205.	0.6	23
673	Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial. Clinical Rheumatology, 2018, 37, 3285-3296.	1.0	14
674	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. Psoriasis: Targets and Therapy, 2018, Volume 8, 49-58.	1.2	9
675	Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of <sc>GPP</sc>. Journal of Dermatology, 2018, 45, 1235-1270.	0.6	159
676	Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. Acta Dermato-Venereologica, 2018, 98, 98-102.	0.6	21
677	Preparing patients for biologic medications for dermatologic and rheumatic diseases. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 23-28.	0.1	6
678	Psoriasis Area and Severity Index response in moderate-to-severe psoriatic patients switched to adalimumab: results from the <sc>OPPSA</sc> study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1737-1744.	1.3	16

#	ARTICLE	IF	CITATIONS
679	Biologics. Updates in Clinical Dermatology, 2018, , 73-92.	0.1	0
680	Antipsoriatic Effects of Wannachawee Recipe on Imiquimod-Induced Psoriasis-Like Dermatitis in BALB/c Mice. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-13.	0.5	36
682	CURRENT TRENDS IN TREATMENT AND MANAGEMENT OF PSORIASIS: AN UPDATED REVIEW. International Research Journal of Pharmacy, 2018, 9, 6-16.	0.0	6
683	Future Therapeutics in Psoriasis. Updates in Clinical Dermatology, 2018, , 93-112.	0.1	1
684	First-in-man intravenous implantation of stromal vascular fraction in psoriasis: a case study. International Medical Case Reports Journal, 2018, Volume 11, 59-64.	0.3	18
685	Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 919-927.	1.5	27
686	A Caseâ€“Control Study to Evaluate Serum Lipoprotein Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2018, 3, 88-93.	0.3	0
687	Therapeutic Efficacies of<i> Artemisia capillaris</i> Extract Cream Formulation in Imiquimod-Induced Psoriasis Models. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-8.	0.5	6
688	Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. Journal of Medical Economics, 2018, 21, 810-820.	1.0	6
689	An Investigation of Comorbid Disease and Health Service Utilization Among Patients With Moderate to Severe Psoriasis in Newfoundland and Labrador. Journal of Cutaneous Medicine and Surgery, 2019, 23, 29-34.	0.6	4
690	Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Diseaseâ€“Modifying Antirheumatic Drug Treatment. Arthritis Care and Research, 2019, 71, 512-520.	1.5	9
691	Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. Journal of Dermatological Treatment, 2019, 30, 141-149.	1.1	23
692	T cellâ€“intrinsic prostaglandin E2-EP2/EP4 signaling is critical in pathogenic TH17 cellâ€“driven inflammation. Journal of Allergy and Clinical Immunology, 2019, 143, 631-643.	1.5	81
693	PresentaciÃ³n inusual de psoriasis ostrÃ©ica y artritis psoriÃ¡sica: resultados despuÃ©s de 10 aÃ±os de manejo con infliximab. Revista Colombiana De ReumatologÃa, 2019, 26, 194-200.	0.0	1
694	Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 131-139.	1.7	7
695	ALAâ€“PDT alleviates the psoriasis by inhibiting JAK signalling pathway. Experimental Dermatology, 2019, 28, 1227-1236.	1.4	14
696	Effectiveness of methotrexate in moderate to severe psoriasis patients: real-world registry data from the Swiss Dermatology Network for Targeted Therapies (SDNTT). Archives of Dermatological Research, 2019, 311, 753-760.	1.1	11
697	Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS ONE, 2019, 14, e0220868.	1.1	118

#	ARTICLE	IF	CITATIONS
698	Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study. <i>Journal of Dermatology</i> , 2019, 46, 752-758.	0.6	12
699	Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study. <i>Journal of Psychosomatic Research</i> , 2019, 124, 109780.	1.2	42
700	<p>Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2491-2502.	2.0	50
701	<p>Investigation of psoriasis skin tissue by label-free multi-modal imaging: a case study on a phototherapy-treated patient</p>. <i>Psoriasis: Targets and Therapy</i> , 2019, Volume 9, 43-57.	1.2	2
702	Biosimilars for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 993-1000.	1.4	30
703	Pharmacodynamics OF TNF Î± inhibitors for the treatment of psoriasis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 913-925.	1.5	24
704	Psoriasis: Best Case Series. <i>Homopathic Links</i> , 2019, 32, 064-076.	0.1	1
705	Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy. <i>Case Reports in Dermatology</i> , 2019, 11, 11-16.	0.3	5
706	Heat Shock Protein 60 in Human Diseases and Disorders. <i>Heat Shock Proteins</i> , 2019, , .	0.2	6
707	Psoriasis Patients Suffer From Worse Periodontal Statusâ€™A Meta-Analysis. <i>Frontiers in Medicine</i> , 2019, 6, 212.	1.2	13
708	Evaluate the effect of cadmium on levels of zinc in scalp hair and blood samples of smoker and nonsmoker psoriatic patients at different stage. <i>Environmental Science and Pollution Research</i> , 2019, 26, 31763-31769.	2.7	5
709	The Dermatology Handbook. , 2019, , .		0
710	Apremilast mechanism of efficacy in systemic-naïve patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. <i>Journal of Dermatological Science</i> , 2019, 96, 126-133.	1.0	9
711	Ocular changes in patients with psoriasis. <i>Clinics in Dermatology</i> , 2019, 37, 663-667.	0.8	18
712	Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody â€™OS2966. <i>Scientific Reports</i> , 2019, 9, 1030.	1.6	18
714	Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature. <i>Current Dermatology Reports</i> , 2019, 8, 6-13.	1.1	0
715	Itch: an underâ€™recognized problem in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1465-1476.	1.3	63
716	Update upon the infection risk in patients receiving TNF alpha inhibitors. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 219-229.	1.0	37

#	ARTICLE	IF	CITATIONS
717	Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey. <i>Journal of Rheumatology</i> , 2019, 46, 587-594.	1.0	4
718	Auricular acupressure as a complementary therapy for psoriasis vulgaris: study protocol for a multicenter randomized controlled trial. <i>Trials</i> , 2019, 20, 358.	0.7	3
719	Pharmacodynamic Evaluation: <i>Dermatology.</i> , 2019, , 1-17.		0
720	Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. <i>Current Medical Research and Opinion</i> , 2019, 35, 1751-1759.	0.9	14
721	Exploration of the Product of the 5-Point Investigatorâ€™s Global Assessment and Body Surface Area (IGA A— BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis. <i>Dermatology</i> , 2019, 235, 348-354.	0.9	8
722	Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes. <i>Chonnam Medical Journal</i> , 2019, 55, 75.	0.5	4
723	Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. <i>Global & Regional Health Technology Assessment</i> , 2019, 2019, 228424031882228.	0.2	2
724	Mesenchymal Stem Cell Conditioned Media Ameliorate Psoriasis Vulgaris: A Case Study. <i>Case Reports in Dermatological Medicine</i> , 2019, 2019, 1-5.	0.1	23
725	Psoriasis treatment patterns: a retrospective claims study. <i>Current Medical Research and Opinion</i> , 2019, 35, 1727-1733.	0.9	12
726	Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 324.	1.6	50
727	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 133-142.	0.3	2
728	Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. <i>BMJ Open</i> , 2019, 9, e027535.	0.8	44
729	Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1650-1657.	0.6	20
730	Expert consensus on the persistence of biological treatments in moderateâ€™toâ€™severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1214-1223.	1.3	8
731	<p>Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 1587-1595.	3.3	109
732	Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 282-288.	0.6	3
733	<i>Artemisia anomala</i> extracts enhance the viability and antioxidation capacity of human keratinocytes. <i>Tropical Journal of Pharmaceutical Research</i> , 2019, 18, 61.	0.2	4
734	Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 295-306.	3.3	19

#	ARTICLE	IF	CITATIONS
735	Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis. <i>Journal of Pharmacological Sciences</i> , 2019, 139, 289-303.	1.1	26
736	Liquid crystalline nanoreservoir releasing a highly skin-penetrating berberine oleate complex for psoriasis management. <i>Nanomedicine</i> , 2019, 14, 931-954.	1.7	39
737	The anti-angiogenic effect of tryptanthrin is mediated by the inhibition of apelin promoter activity and shortened mRNA half-life in human vascular endothelial cells. <i>Phytomedicine</i> , 2019, 58, 152879.	2.3	11
738	Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model. <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 826-838.	0.9	55
739	Association between geographic tongue and psoriasis: A systematic review and meta-analysis. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 365-372.	1.4	16
740	Treating to Target(s) With Interleukin-17 Inhibitors. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 3S-34S.	0.6	6
741	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	0.6	542
742	Introductory Chapter: Psoriasis as a Whole. , 2019, , .		0
743	An analysis of selected factors influencing the efficacy of psoriasis therapy. <i>Przegląd Dermatologiczny</i> , 2019, 106, 603-614.	0.0	1
744	Unusual presentation of psoriasis ostracea and psoriatic arthritis: Results after 10 years of infliximab treatment. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2019, 26, 194-200.	0.1	0
745	Effect of Korean medicine as add-on therapy to phototherapy for psoriasis. <i>Medicine (United States)</i> , 2019, 98, e14526.	0.4	3
746	Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1366-1376.	0.5	13
747	Diagnostic role of ultrasound elastography for nail bed involvement in psoriasis. <i>Medicine (United States)</i> , 2019, 98, e14526.	0.4	4
748	Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1025-1029.	0.8	1
749	The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. <i>PLoS ONE</i> , 2019, 14, e0225112.	1.1	18
750	Considerable variation among Iranian dermatologists in the knowledge and attitudes regarding the use of biologic agents to manage psoriasis,. <i>International Journal of Women's Dermatology</i> , 2019, 5, 356-360.	1.1	1
751	Serum elafin as a potential inflammatory marker in psoriasis. <i>International Journal of Dermatology</i> , 2019, 58, 205-209.	0.5	22
752	Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis. <i>Annals of Pharmacotherapy</i> , 2019, 53, 276-284.	0.9	12

#	ARTICLE	IF	CITATIONS
753	Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 479-488.	0.5	39
754	Psoriasis: Which therapy for which patient. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 27-40.	0.6	271
755	A Gut Commensal Bacterium Promotes Mosquito Permissiveness to Arboviruses. <i>Cell Host and Microbe</i> , 2019, 25, 101-112.e5.	5.1	154
756	Psoriasis y depresi3n: el papel de la inflamaci3n. <i>Actas Dermo-sifilogr3ficas</i> , 2019, 110, 12-19.	0.2	43
757	The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. <i>Journal of Dermatological Treatment</i> , 2019, 30, 446-453.	1.1	9
758	Psoriasis and Depression: The Role of Inflammation. <i>Actas Dermo-sifilogr3ficas</i> , 2019, 110, 12-19.	0.2	29
759	Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1107-1115.	1.3	20
760	The Importance of Achieving Clear or Almost Clear Skin for Patients: Results from the Nordic Countries of the Global "Clear about Psoriasis" Patient Survey. <i>Acta Dermato-Venereologica</i> , 2019, 99, 158-163.	0.6	15
761	Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. <i>Rheumatology International</i> , 2019, 39, 121-130.	1.5	19
762	Biologics and Psoriasis. <i>Dermatologic Clinics</i> , 2019, 37, 29-36.	1.0	43
763	Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 204-221.	0.6	28
764	Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study. <i>Journal of Medical Economics</i> , 2019, 22, 53-62.	1.0	5
765	Periodontitis as another comorbidity associated with psoriasis: A case-control study. <i>Journal of Periodontology</i> , 2019, 90, 358-366.	1.7	26
766	Redox imbalance and IL-17 responses in memory CD4+ T cells from patients with psoriasis. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12730.	1.3	12
767	Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 454-460.	1.1	15
768	Metformin inhibits pro-inflammatory responses via targeting nuclear factor- κ B in HaCaT cells. <i>Cell Biochemistry and Function</i> , 2019, 37, 4-10.	1.4	28
769	Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK. <i>Journal of Dermatological Treatment</i> , 2019, 30, 376-382.	1.1	3
770	Use of cosmetic products for treating certain diseases—Know the science. <i>Journal of Cosmetic Dermatology</i> , 2019, 18, 221-225.	0.8	1

#	ARTICLE	IF	CITATIONS
771	Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. <i>Journal of Dermatological Treatment</i> , 2020, 31, 452-459.	1.1	4
772	US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 31, 333-341.	1.1	23
773	A cross-sectional study of YouTube videos as a source of patient information about topical psoriasis therapies. <i>Journal of Dermatological Treatment</i> , 2020, 31, 366-369.	1.1	14
774	Biologics monitoring: incongruity between recommendations and clinician monitoring trends. <i>Journal of Dermatological Treatment</i> , 2020, 31, 450-451.	1.1	1
775	Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 763-768.	1.1	9
776	Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). <i>British Journal of Dermatology</i> , 2020, 183, 265-275.	1.4	24
777	Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population. <i>Journal of Dermatological Treatment</i> , 2021, 32, 595-602.	1.1	12
778	Japanese guidance for use of biologics for psoriasis (the 2019 version). <i>Journal of Dermatology</i> , 2020, 47, 201-222.	0.6	58
779	Psoriatic Disease in the US Latino Population: A Comprehensive Review. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 265-274.	3.3	9
780	In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 173-182.	1.4	29
781	Anti-psoriatic and immunomodulatory evaluation of psorospermum febrifugum spach and its phytochemicals. <i>Scientific African</i> , 2020, 7, e00229.	0.7	7
782	A potential association between psoriasis to rs4819554 of IL-17RA gene polymorphism in psoriasis Egyptian patients. <i>Archives of Dermatological Research</i> , 2020, 312, 273-281.	1.1	8
783	Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. <i>Clinical Pharmacokinetics</i> , 2020, 59, 311-326.	1.6	20
784	<p>The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East</p>. <i>Psoriasis: Targets and Therapy</i> , 2020, Volume 10, 23-28.	1.2	1
785	Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis. <i>Dermatology and Therapy</i> , 2020, 10, 1383-1396.	1.4	3
786	Increased biologic utilization in Latino patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2020, , 1-4.	1.1	2
787	Real-world switch patterns and healthcare costs in biologic-naïve psoriasis patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 767-779.	0.6	8
788	Optimizing the Treatment of Moderate-to-Severe Psoriasis in Older Adults. <i>Drugs and Aging</i> , 2020, 37, 715-723.	1.3	6

#	ARTICLE	IF	CITATIONS
789	<p>Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis</p>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 369-377.	0.7	10
790	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). Dermatology and Therapy, 2020, 10, 1099-1109.	1.4	13
791	Adalimumab-Associated Hemorrhagic Pericarditis. American Journal of Therapeutics, 2020, 27, e630-e632.	0.5	2
792	The association of serum vascular endothelial growth factor levels and psoriasis vulgaris. Medicine (United States), 2020, 99, e21565.	0.4	0
793	Psoriatic patients undergoing long-term therapy with biologics: Impact of residual localization of psoriasis on quality of life in an Italian clinical setting. Dermatologic Therapy, 2020, 33, e14337.	0.8	4
794	Efficacy and safety of fire needle therapy for blood stasis syndrome of plaque psoriasis: protocol for a randomized, single-blind, multicenter clinical trial. Trials, 2020, 21, 739.	0.7	5
795	The Protective Effects of 18<i>Î</i>-Glycyrrhetic Acid on Imiquimod-Induced Psoriasis in Mice via Suppression of mTOR/STAT3 Signaling. Journal of Immunology Research, 2020, 2020, 1-9.	0.9	12
796	Pain associated with psoriasis: systematic scoping review protocol. BMJ Open, 2020, 10, e031461.	0.8	2
797	Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users: A retrospective cohort study. JGH Open, 2020, 4, 1211-1216.	0.7	2
798	Incentives for Danish healthcare management based on a pilot outcome-based, patient-centric management model in psoriasis and psoriatic arthritis: the non-interventional IMPROVE study. Archives of Public Health, 2020, 78, 95.	1.0	5
799	Hydrogel-Based Active Substance Release Systems for Cosmetology and Dermatology Application: A Review. Pharmaceutics, 2020, 12, 396.	2.0	71
800	Chinese Medicine for Psoriasis Vulgaris Based on Syndrome Pattern: A Network Pharmacological Study. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-16.	0.5	4
801	A Randomized Controlled Trial with a Medical Device Containing Sodium Hyaluronate and Nicotinic Acid to Increase the Efficacy of Ultraviolet Phototherapy in Psoriasis. Dermatology and Therapy, 2020, 10, 651-662.	1.4	0
802	Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma. Journal of Dermatological Treatment, 2022, 33, 531-534.	1.1	12
803	Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review. Journal of Dermatological Treatment, 2020, , 1-6.	1.1	1
804	PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. Journal of the American Academy of Dermatology, 2020, 83, 131-138.	0.6	9
805	Balneotherapy with Chinese herbal medicine prolongs the remission period in patients with psoriasis vulgaris. Dermatologic Therapy, 2020, 33, e13351.	0.8	6
806	To explore the clinical efficacy of Traditional Chinese Medicine bath in the treatment of psoriasis vulgaris with blood-heat syndrome and its effect on related cytokines based on different temperature and different concentration. Medicine (United States), 2020, 99, e20172.	0.4	10

#	ARTICLE	IF	CITATIONS
807	Anti-CD6 mAbs for the treatment of psoriasis. Expert Opinion on Biological Therapy, 2020, 20, 1215-1222.	1.4	7
808	Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis. Drug Delivery, 2020, 27, 662-680.	2.5	28
809	Immune Modulation of Monocytes Dampens the IL-17+ γ T Cell Response and Associated Psoriasis Pathology in Mice. Journal of Investigative Dermatology, 2020, 140, 2398-2407.e1.	0.3	5
810	Study of Efficacy and Safety of Acitretin as Monotherapy in the Treatment of Moderate to Severe Plaque Type Psoriasis. Faridpur Medical College Journal, 2020, 14, 16-19.	0.0	0
811	A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis. Dermatologic Therapy, 2020, 33, e13802.	0.8	11
812	Safety and efficacy of Chinese herbal bath for psoriasis vulgaris. Medicine (United States), 2020, 99, e20488.	0.4	0
814	Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment, 2022, 33, 740-748.	1.1	5
815	Use of a new cold plasma tool for psoriasis treatment: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2092270.	0.2	9
816	Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. Journal of the American Academy of Dermatology, 2020, 83, 96-103.	0.6	47
817	Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis. Journal of Dermatological Treatment, 2020, 31, 460-469.	1.1	6
818	Safety concerns with current treatments for psoriasis in the elderly. Expert Opinion on Drug Safety, 2020, 19, 523-531.	1.0	20
819	Safety considerations with combination therapies for psoriasis. Expert Opinion on Drug Safety, 2020, 19, 489-498.	1.0	14
820	Nanostructured lipidic carriers for dual drug delivery in the management of psoriasis: Systematic optimization, dermatokinetic and preclinical evaluation. Journal of Drug Delivery Science and Technology, 2020, 57, 101775.	1.4	34
821	Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study. Journal of Dermatological Treatment, 2020, , 1-7.	1.1	3
822	Efficacy and safety of adalimumab in difficult-to-treat psoriasis. Dermatologic Therapy, 2020, 33, e13374.	0.8	14
823	Microneedles: a potential strategy in transdermal delivery and application in the management of psoriasis. RSC Advances, 2020, 10, 14040-14049.	1.7	44
824	Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert Opinion on Drug Safety, 2020, 19, 423-432.	1.0	8
825	Narrow band ultraviolet B therapy deactivates Th1/Th17 pathway and activates Th2 cytokines secretion in Egyptian psoriatic arthritis patients. Journal of Radiation Research and Applied Sciences, 2020, 13, 356-361.	0.7	11

#	ARTICLE	IF	CITATIONS
826	Decoding active components in a formulation of multiple herbs for treatment of psoriasis based on three cell lines fishing and liquid chromatography-mass spectrometry analysis. Journal of Pharmaceutical and Biomedical Analysis, 2020, 186, 113331.	1.4	12
827	Successful Treatment of Plaque Psoriasis with Allogeneic Gingival Mesenchymal Stem Cells: A Case Study. Case Reports in Dermatological Medicine, 2020, 2020, 1-4.	0.1	13
828	Feature selection and pattern recognition for different types of skin disease in human body using the rough set method. Network Modeling Analysis in Health Informatics and Bioinformatics, 2020, 9, 1.	1.2	11
829	Role of phototherapy in the era of biologics. Journal of the American Academy of Dermatology, 2021, 84, 479-485.	0.6	48
830	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 123-134.	1.3	25
831	Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology, 2021, 237, 46-55.	0.9	16
832	Intermittent use of biologic agents for the treatment of psoriasis in adults. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 360-367.	1.3	14
833	Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. Journal of the American Academy of Dermatology, 2021, 84, 1059-1067.	0.6	92
834	A Description of Treatment Patterns of Psoriasis by Medical Providers and Disease Severity in US Women. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 45-51.	0.3	1
835	Shear wave elastography and microvascular ultrasound in response evaluation to calcipotriol+betamethasone foam in plaque psoriasis. Postgraduate Medical Journal, 2021, 97, 16-22.	0.9	3
836	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 450-457.	1.3	14
837	Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 912-918.	1.3	5
838	Major depressive disorder increased risk of psoriasis: A propensity score matched cohort study. Journal of Affective Disorders, 2021, 278, 407-412.	2.0	15
839	Probiotic Research in Therapeutics. , 2021, , .		1
840	Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 417-421.	1.3	11
841	Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. Journal of Dermatological Treatment, 2021, 32, 56-63.	1.1	8
842	Formulation and Evaluation of Polyherbal Cream and Lotion for the Treatment of Psoriasis-Induced Secondary Infections. Current Reviews in Clinical and Experimental Pharmacology, 2021, 16, 79-96.	0.4	4
843	The Role of Leptin in the Association between Obesity and Psoriasis. Biomolecules and Therapeutics, 2021, 29, 11-21.	1.1	26

#	ARTICLE	IF	CITATIONS
844	Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review. <i>Drugs</i> , 2021, 81, 349-366.	4.9	20
845	Inflammatory Disorders: Psoriasis, Lichen Planus, Pityriasis Rosea, and Sarcoidosis. <i>Updates in Clinical Dermatology</i> , 2021, , 91-101.	0.1	0
846	Capsaicin: Plants of the Genus <i>Capsicum</i> and Positive Effect of Oriental Spice on Skin Health. <i>Skin Pharmacology and Physiology</i> , 2020, 33, 331-341.	1.1	3
847	Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 720.	1.8	47
848	Etiological Association Between Psoriasis and Thyroid Diseases. <i>Cureus</i> , 2021, 13, e12653.	0.2	2
849	Characteristics of patients with psoriatic arthritis treated with ustekinumab. Evidence from real-life clinical practice. <i>Meditinskiy Sovet</i> , 2021, , 274-283.	0.1	0
850	Assessment of Micro-Albuminuria and Renal Artery Resistance Index in Psoriatic Patients. <i>Benha Journal of Applied Sciences</i> , 2021, 6, 21-25.	0.0	0
851	Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective. <i>Research in Pharmaceutical Sciences</i> , 2021, 16, 381.	0.6	0
852	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1661-1669.	1.1	15
853	Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study. <i>Dermatology and Therapy</i> , 2021, 11, 513-528.	1.4	11
854	Fixed-dose combination calcipotriol/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 20-27.	1.3	5
855	Knowledge and Practices of Community Pharmacists in Topical Dermatological Treatments. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2928.	1.2	7
856	Study on serum copper, zinc and selenium trace element levels in Psoriasis. <i>IP Indian Journal of Clinical and Experimental Dermatology</i> , 2021, 5, 239-242.	0.0	0
857	Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1031.	1.0	19
858	Circulating long noncoding RNA growth arrest-specific transcript 5 as a diagnostic marker and indicator of degree of severity in plaque psoriasis. <i>International Journal of Dermatology</i> , 2021, 60, 973-979.	0.5	9
859	A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 624-631.	0.6	31
860	Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 53-57.	0.2	1
861	Pentacyclic triterpene compounds from loquat leaves reduce skin inflammation and epidermal hyperplasia in psoriasis via inhibiting the Th17 cells. <i>Molecular Immunology</i> , 2021, 132, 30-40.	1.0	7

#	ARTICLE	IF	CITATIONS
862	Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 425-442.	3.3	55
863	Early detection of subclinical lower limb enthesopathy by ultrasonography in patients with psoriasis: Relation to disease severity. <i>Egyptian Rheumatologist</i> , 2021, 43, 153-157.	0.5	7
864	Graphene Oxide Topical Administration: Skin Permeability Studies. <i>Materials</i> , 2021, 14, 2810.	1.3	11
865	The paeonol target gene autophagy-related 5 has a potential therapeutic value in psoriasis treatment. <i>PeerJ</i> , 2021, 9, e11278.	0.9	4
866	The effects of acupuncture for patients with psoriasis. <i>Medicine (United States)</i> , 2021, 100, e26042.	0.4	3
867	Guidelines for Management of Psoriasis. <i>Journal of the Dermatology Nurses' Association</i> , 2021, 13, 168-174.	0.1	1
868	New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab. <i>Meditinskiy Sovet</i> , 2021, , 40-50.	0.1	0
869	Clinical and molecular significance of genetic loci associated with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101691.	1.4	5
870	Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. , 2022, 229, 107925.		16
871	Viewing Psoriasis as a Systemic Disease for Better Health Outcomes. <i>JID Innovations</i> , 2021, 1, 100007.	1.2	2
872	Evaluation of NLRP3 (rs10754558) and PTPN22 (1858C/T) (rs2476601) Functional Polymorphisms in Psoriasis Susceptibility in Egypt. <i>The Application of Clinical Genetics</i> , 2021, Volume 14, 331-339.	1.4	3
873	Tyrosine kinase 2 and Janus kinase signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 148-157.	0.6	51
874	Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy in naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1686-1691.	1.3	12
875	Treatment of psoriasis in end-stage renal disease patients is associated with decreased mortality: A retrospective cohort study. <i>American Journal of the Medical Sciences</i> , 2021, 362, 24-33.	0.4	9
876	Economic Evaluation of The Budget Impact of Precision Medicine Testing for The Treatment of Psoriasis. <i>SKIN the Journal of Cutaneous Medicine</i> , 2021, 5, 372-387.	0.1	3
877	Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). <i>Journal of Dermatological Treatment</i> , 2021, , 1-15.	1.1	1
878	Outcome domains and measures for pain in psoriasis used in registered trials: analysis of studies on ClinicalTrials.gov. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 909-915.	0.6	2
879	Microneedles-based drug delivery for the treatment of psoriasis. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 64, 102668.	1.4	15

#	ARTICLE	IF	CITATIONS
880	Combination therapy of recalcitrant severe psoriasis with psoriatic arthritis, diabetes nephropathy, and liver cirrhosis. <i>Journal of Cosmetic Dermatology</i> , 2021, , .	0.8	3
881	Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. <i>Dermatology and Therapy</i> , 2021, 11, 1717-1732.	1.4	2
882	Nevi, biologics for psoriasis and the risk for skin cancer: A real concern? (Case presentation and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.8	1
883	Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 120-130.	0.2	1
884	Quality of life and patientâ€perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixedâ€dose combination Cal/BD foam: A <i>postâ€hoc</i> analysis of PSOâ€LONG. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 60-67.	1.3	6
885	Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1965-1998.	1.4	14
886	Tacrolimus-loaded chitosan nanoparticles for enhanced skin deposition and management of plaque psoriasis. <i>Carbohydrate Polymers</i> , 2021, 268, 118238.	5.1	31
887	Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients. <i>Dermatology and Therapy</i> , 2021, 11, 1791-1804.	1.4	4
888	Plantar Psoriasis. <i>Clinics in Podiatric Medicine and Surgery</i> , 2021, 38, 541-552.	0.2	1
889	Burden of Disease for Psoriasis in Argentina, Brazil, Colombia, and Mexico. <i>Value in Health Regional Issues</i> , 2021, 26, 126-134.	0.5	1
890	Circulating microRNA profile unveils mechanisms of action of acitretin for psoriasis vulgaris. <i>Bioengineered</i> , 2021, 12, 1838-1850.	1.4	2
891	Inflammatory Disorders. , 2017, , 129-141.		1
892	Psoriasis: Overview and Diagnosis. <i>Updates in Clinical Dermatology</i> , 2018, , 1-16.	0.1	15
894	Investigating Personality and Psychopathology in Patients With Psoriasis. <i>Rorschachiana</i> , 2017, 38, 87-107.	0.3	3
895	Dermatologistsâ€™ Awareness of and Screening Practices for Hepatitis B Virus Infection Before Initiating Tumor Necrosis Factor-Î± Inhibitor Therapy. <i>Southern Medical Journal</i> , 2011, 104, 781-788.	0.3	20
897	Conventional ultrasonography and sonoelastography in the assessment of plaque psoriasis under topical corticosteroid treatment â€“ work in progress. <i>Medical Ultrasonography</i> , 2014, 16, 107-113.	0.4	23
898	A Brief History of Psoriasis Management in Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 273-277.	0.6	1
899	Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis. , 2020, 106, E15-E17.		3

#	ARTICLE	IF	CITATIONS
900	Introduction. Seminars in Cutaneous Medicine and Surgery, 2014, 33, S19-S19.	1.6	6
901	ALIGN PsA: Advancing a Multidisciplinary Approach in PsA. Seminars in Cutaneous Medicine and Surgery, 2018, 37, S125-S135.	1.6	6
903	Conceitos atuais e relevantes sobre artrite psoriásica. Revista Brasileira De Reumatologia, 2012, 52, 98-106.	0.8	16
904	Pathogenesis and therapy of psoriasis and psoriatic arthritis. Klinicheskaya Dermatologiya i Venerologiya, 2019, 18, 634.	0.0	5
905	METHOTREXATE; OUTCOME IN THE TREATMENT OF PLAQUE PSORIASIS. The Professional Medical Journal, 2017, 24, 607-611.	0.0	2
906	Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature. Clinical, Cosmetic and Investigational Dermatology, 2010, 3, 49.	0.8	3
907	<p>Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis</p>. Journal of Inflammation Research, 2020, Volume 13, 53-60.	1.6	16
908	Therapeutic Strategies to Protect the Central Nervous System against Shiga Toxin from Enterohemorrhagic Escherichia coli. Current Neuropharmacology, 2020, 19, 24-44.	1.4	11
909	Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis. Current Rheumatology Reviews, 2019, 15, 234-237.	0.4	22
910	Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 441-451.	0.8	5
911	Maximal Use Study of Tapinarof Cream 1% in Subjects with Extensive Plaque Psoriasis. SKIN the Journal of Cutaneous Medicine, 2020, 4, s74.	0.1	4
912	Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials. SKIN the Journal of Cutaneous Medicine, 2020, 4, s75.	0.1	9
913	Urinary biopyrrins: A new marker of oxidative stress in psoriasis. Indian Journal of Dermatology, 2016, 61, 169.	0.1	8
914	Biologics use in Indian psoriasis patients. Indian Dermatology Online Journal, 2016, 7, 489.	0.2	9
915	Association of psoriasis with asthma: A systematic review and meta-analysis of observational studies. Dermatologica Sinica, 2020, 38, 22.	0.2	11
916	Peroxisome proliferator-activated receptor-Î³ gene polymorphism in psoriasis and its relation to obesity, metabolic syndrome, and narrowband ultraviolet B response: A caseâ€“control study in Egyptian patients. Indian Journal of Dermatology, 2019, 64, 192.	0.1	14
917	Real-world insight on apremilast therapy in patients with plaque psoriasis: Indian experience. Indian Journal of Dermatology, 2020, 65, 396.	0.1	2
918	18F-fluorodeoxyglucose positron emission tomography-based evaluation of systemic and vascular inflammation and assessment of the effect of systemic treatment on inflammation in patients with moderate-to-severe psoriasis: A randomized placebo-controlled pilot study. Indian Journal of Dermatology, Venereology and Leprology, 2018, 84, 660.	0.2	13

#	ARTICLE	IF	CITATIONS
919	Kasr AL-Ainyâ€™s psoriasis unit protocol for the treatment of psoriasis, part II: biological therapies. Journal of the Egyptian Women's Dermatologic Society, 2019, 16, 73.	0.2	1
920	Kasr AL-Ainyâ€™s psoriasis unit protocol for the management of psoriasis, part I: topical and systemic therapies. Journal of the Egyptian Women's Dermatologic Society, 2019, 16, 1.	0.2	1
921	Activated protein C: A regulator of human skin epidermal keratinocyte function. World Journal of Biological Chemistry, 2014, 5, 169-79.	1.7	32
922	Differences in expression of genes related to drug resistance and miRNAs regulating their expression in skin fibroblasts exposed to adalimumab and cyclosporine A. Postepy Dermatologii I Alergologii, 0, , .	0.4	3
923	Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study. European Journal of Rheumatology, 2017, 4, 24-28.	1.3	20
924	Targeting IL-17 in psoriatic arthritis. European Journal of Rheumatology, 2017, 4, 272-277.	1.3	32
925	Biologic Therapy for Psoriatic Arthritis or Moderate to Severe Plaque Psoriasis: Systematic Review with Pairwise and Network Meta-Analysis. International Journal of Statistics in Medical Research, 2014, 3, 74-87.	0.5	5
926	Is There Any Association Between Psoriasis and Hashimotoâ€™s Thyroiditis?. Cureus, 2019, 11, e4269.	0.2	10
927	Efficacy and safety of acupuncture therapy for psoriasis: an overview of systematic reviews. Annals of Palliative Medicine, 2021, 10, 10804-10820.	0.5	0
929	Psoriasisâ€™Neues VerstÃ¤ndnis einer alten Erkrankung. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2009, , 175-179.	0.0	0
932	TNF- Î±-blokkade in de dagelijkse praktijk. , 2011, , 7-26.		0
934	Telepsoriasis. , 2012, , 103-112.		0
935	NORMAS DE BOA PRÃƒTICA PARA O TRATAMENTO DA PSORÃƒASE EM PLACAS EM IDADE NÃƒO PEDIÃƒTRICA COM BIOLÃƒGICOS. Journal of the Portuguese Society of Dermatology and Venereology, 2011, 69, 532.	0.0	2
937	Ustekinumab: a guide to its use in plaque psoriasis. Drugs and Therapy Perspectives, 2012, 28, 6-10.	0.3	0
938	Mycobacterium porferae infection in a psoriasis patient on anti-tnf-a therapy. Dermatology Online Journal, 2013, 19, .	0.2	3
939	The Association Between Psoriasis and Cardiovascular Diseases. Electronic Journal of General Medicine, 2013, 10, .	0.3	1
942	Psoriatic Arthritis: Clinical Review and Update. , 2014, , 39-61.		0
943	Summary of Published Treatment Guidelines. , 2014, , 301-313.		0

#	ARTICLE	IF	CITATIONS
945	Common Dermatoses. , 2014, , 1-23.		0
946	Corticosteroid Cream Once Daily plus an Emollient Cream in comparison with Corticosteroid Cream Twice Daily in Plaque Psoriasis: An Intra- Patient, Randomized Assessor-Blinded, Ultrasound Evaluation Study. Journal of Clinical & Experimental Dermatology Research, 2014, 05, .	0.1	1
947	Multiple Skin Cancers Following Psoralen and Ultraviolet A Treatment of Psoriasis. Archives of Craniofacial Surgery, 2014, 15, 145.	0.4	1
948	Infliximab and Golimumab. , 2014, , 177-196.		0
949	Comparative Risk-Benefit Analysis of Different Classes of Biologic Agents in Patients with Psoriasis: A Case Study on the Pros and Cons of Mixed Treatment Comparison in Synthesizing Complex Evidence Networks. International Journal of Statistics in Medical Research, 2014, 3, 231-247.	0.5	0
950	Chapter 33: Scaly Dermatoses. , 2015, , .		0
951	PSORIAZINE ARTROPATIJA SERGANÄCEIÄ²JÄ², HOSPITALIZUOTÄ² 2013 METAIS DERMATOVENEROLOGIJOS CENTRE ANALIZÄ–. Health Sciences, 2015, 25, 78-84.	0.0	0
952	Current evidence on the effectiveness of systemic herbal medicine for psoriasis: A systematic review with meta-analysis. Global Dermatology, 2015, 2, .	0.1	1
953	Skin Findings with Systemic Associations. , 2015, , 13-134.		0
954	PsÄ²riazisin YÄ²netiminde Tedavi SeÄ²enekleri. Arsiv Kaynak Tarama Dergisi, 2015, 24, 339.	0.1	0
955	Assessment of attitudes towards the use of topical corticosteroids among patients, prescribers and pharmacists in the Republic of Macedonia. Makedonsko Farmaceutski Bilten, 2016, 62, 25-34.	0.0	3
956	Assessment of the therapeutic aspect of systemic non-biologic anti-psoriatic treatment modalities used in combination with methotrexate. Indian Journal of Dermatology, 2016, 61, 118.	0.1	5
957	Fixed combination of calcipotriol and betamethasone dipropionate in the treatment of psoriasis: case-based analysis. Klinicheskaya Dermatologiya I Venerologiya, 2016, 15, 85.	0.0	0
958	PSÄ–RÄ°ATÄ°K ARTRÄ°T TEDAVÄ°SÄ°: 2015 GÄœNCELLEME / PSORIATIC ARTHRITIS TREATMENT: 2015 UPDATE. OsmangazÄ° Journal of Medicine, 2016, 38, .	0.1	1
959	Status of Serum Leptin and Lipid Profile in Newly Diagnosed Psoriasis Patients: A Case Control Study. Journal of Medical Science and Clinical Research, 0, , .	0.0	0
960	Comparison between domestic and foreign Clinical guidelines and previous researches on Korean medicine for psoriasis to develop the clinical trial guideline of psoriasis using Korean medicine. The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology, 2016, 29, 12-32.	0.0	0
961	Common Dermatoses. , 2017, , 1563-1583.		0
963	A curative approach for psoriasis vulgaris. International Journal of Pharma and Bio Sciences, 2017, 8, .	0.1	0

#	ARTICLE	IF	CITATIONS
965	Chapter 34: Scaly Dermatoses. , 2017, , .		1
966	Frequent dermatological disordersâ€™ pharmacotherapy. Adverse drugs effects with cutaneous manifestations. Farmacist Ro, 2018, 6, 10.	0.0	0
967	New Calcipotriol/Betamethasone Dipropionate Foam Formulation for the Treatment of Psoriasis: An Overview. Journal of the Portuguese Society of Dermatology and Venereology, 2018, 76, 53-64.	0.0	0
969	Solasodine Glycosides from the Eggplant in a Topical Cream Psorend<sup>BEC</sup> Are Effective against Psoriasis. International Journal of Clinical Medicine, 2019, 10, 174-182.	0.1	1
970	Heat Shock Protein 60 in Skin Diseases. Heat Shock Proteins, 2019, , 347-359.	0.2	0
971	Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients. Serbian Journal of Dermatology and Venereology, 2019, 11, 13-18.	0.2	1
973	Possibility of combined therapy with an oral phosphodiesterase-4 inhibitor (apremilast) and dihydrofolatereductase inhibitor (methotrexate) in patients with psoriatic arthritis plaque psoriasis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 292-298.	0.2	0
974	Assessing the Prevalence of Type 2 Diabetes in Patients with Psoriasis Referred to Sina Hospital, Hamadan, Iran. Avicenna Journal of Clinical Medicine, 2019, 26, 143-150.	0.1	0
975	Cognitive impairment in patients with psoriasis: A clinical study in teaching hospital. Journal of Family Medicine and Primary Care, 2020, 9, 4001.	0.3	3
976	Ethnobotanical Study of Medicinal Plants used in Skin Diseases in the Area Alamut-Qazvin, Iran. Journal of Medicinal Plants, 2020, 4, 121-132.	0.3	0
977	Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 212-219.	0.8	4
978	AN APPROACH FOR THE TREATMENT OF PSORIASIS: PHARMACOLOGICAL & NON-PHARMACOLOGICAL THERAPY. , 2020, 5, 429-435.		0
979	Therapeutic implications of narrow band ultraviolet B on psoriasis severity and serum levels of acute phase reactants. Dermatologic Therapy, 2020, 33, e13856.	0.8	0
980	â€ˆPsoriasisâ€™ reduces Tâ€™lymphocyteâ€™ mediated inflammation in patients with psoriasis by inhibiting vitaminâ€™D receptorâ€™ mediated STAT4 inactivation. International Journal of Molecular Medicine, 2020, 46, 1538-1550.	1.8	4
981	Common Dermatoses. , 2020, , 1-8.		0
982	Abordaje diagnÃ³stico y manejo de psoriasis en atenciÃ³n primaria. AtenciÃ³n Familiar, 2020, 28, 54.	0.0	0
983	Pharmacodynamic Evaluation: Dermatology. , 2020, , 299-315.		0
985	Viva voce: Adalimumab. Indian Journal of Drugs in Dermatology, 2020, 6, 53.	0.0	0

#	ARTICLE	IF	CITATIONS
986	Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 727-733.	0.4	1
987	Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. <i>Journal of Dermatological Treatment</i> , 2021, 32, 916-921.	1.1	6
988	HSP90 inhibitor RGRNâ€³05 for oral treatment of plaqueâ€¢type psoriasis: efficacy, safety and biomarker results in an openâ€¢label proofâ€¢ofâ€¢concept study*. <i>British Journal of Dermatology</i> , 2022, 186, 861-874.	1.4	19
989	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis. <i>Frontiers in Pharmacology</i> , 2021, 12, 774808.	1.6	16
990	Evaluation of anti-psoriatic activity of selected phytochemicals on UV-induced psoriasis in mouse tail model. <i>Indian Journal of Physiology and Pharmacology</i> , 0, 64, 123-128.	0.4	0
992	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 400-410.	0.8	9
993	Plaque Psoriasis Successfully Treated with an Individualised Homoeopathic Medicine Lycopodium: A Case Report. <i>Homopathic Links</i> , 0, , .	0.1	3
995	Adalimumab for Psoriasis. , 2021, , 153-172.		0
996	Infliximab, Golimumab, and Certolizumab Pegol. , 2021, , 173-199.		0
997	Psoriasis and Comorbidities. , 2021, , 363-397.		0
998	Chapter 34: Scaly Dermatoses. , 2020, , .		0
999	Probiotics in Autoimmune and Inflammatory Diseases. , 2021, , 251-271.		1
1000	Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2009, 2, 29-35.	0.1	2
1001	A practical approach to monitoring patients on biological agents for the treatment of psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2010, 3, 20-6.	0.1	6
1002	The burden of psoriatic arthritis: a literature review from a global health systems perspective. <i>P and T</i> , 2010, 35, 680-9.	1.0	92
1003	A practical approach to screening psoriasis patients for therapy with biologic agents. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2008, 1, 50-4.	0.1	4
1005	Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis. <i>Ontario Health Technology Assessment Series</i> , 2009, 9, 1-66.	3.0	5
1006	Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician. <i>Canadian Family Physician</i> , 2012, 58, e390-400.	0.1	5

#	ARTICLE	IF	CITATIONS
1007	A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis. <i>Practical Dermatology</i> , 2010, 7, 31-35.	0.0	7
1008	G-231A and G+70C Polymorphisms of Endothelin Receptor Type-A Gene could Affect the Psoriasis Area and Severity Index Score and Endothelin 1 Levels. <i>Indian Journal of Dermatology</i> , 2015, 60, 211.	0.1	3
1009	Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 3156-72.	1.3	20
1010	Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis. <i>P and T</i> , 2015, 40, 495-500.	1.0	24
1011	Pituitary tumor transforming gene PTTG2 induces psoriasis by regulating vimentin and E-cadherin expression. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 10887-93.	0.5	3
1012	More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis. <i>P and T</i> , 2016, 41, 388-90.	1.0	3
1013	Rational Vehicle Design Ensures Targeted Cutaneous Steroid Delivery. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2017, 10, 12-19.	0.1	2
1014	Diagnosis and management of psoriasis. <i>Canadian Family Physician</i> , 2017, 63, 278-285.	0.1	173
1015	The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. <i>American Health and Drug Benefits</i> , 2016, 9, 504-513.	0.5	58
1016	Common Contact Allergens in Patients with Palmoplantar and Scalp Psoriasis and Impact of their Avoidance on Dermatology Life Quality Index: A Hospital-Based Study. <i>Indian Journal of Dermatology</i> , 2018, 63, 160-164.	0.1	2
1017	The Role of Forkhead Box Class O3A and SIRT1 Gene Variants in Early-Onset Psoriasis. <i>Indian Journal of Dermatology</i> , 2018, 63, 208-214.	0.1	4
1018	The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab. <i>American Health and Drug Benefits</i> , 2019, 12, 22-26.	0.5	0
1019	Recommendations for Initiating Systemic Therapy in Patients with Psoriasis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2019, 12, 13-26.	0.1	4
1020	Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2019, 12, 46-54.	0.1	6
1021	The Putative Role of Thyroid Hormones and Vitamin D on Severity and Quality of Life in Psoriasis. <i>International Journal of Applied & Basic Medical Research</i> , 2020, 10, 173-177.	0.2	0
1022	The Psoriasis Decision Tree. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, 14-22.	0.1	0
1023	Systemic Management of Psoriasis Patients in Indian Scenario: An Expert Consensus. <i>Indian Dermatology Online Journal</i> , 2021, 12, 674-682.	0.2	0
1024	How the "œœck Factor" Matters in Chronic Health Conditions. , 2021, , 225-242.		0

#	ARTICLE	IF	CITATIONS
1025	Urologic dermatology: a comprehensive foray into the noninfectious etiologies of balanitis. <i>International Journal of Dermatology</i> , 2022, 61, 1467-1478.	0.5	1
1026	Aryl Hydrocarbon Receptor Repressor Is Hypomethylated in Psoriasis and Promotes Psoriasis-like Inflammation in HaCaT Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12715.	1.8	4
1027	Systemic management of psoriasis patients in Indian scenario: An expert consensus. <i>Indian Dermatology Online Journal</i> , 2021, 12, 674.	0.2	8
1028	Influence of psoriasis lesions' location and severity on psychosocial disability and psychopathology. Observational study and psychometric validation of the SAPASI Portuguese version. <i>Journal of Psychosomatic Research</i> , 2022, 154, 110714.	1.2	1
1029	PSYCHOSOCIAL IMPACT OF COMMON SKIN DISORDERS – A REVIEW STUDY. <i>International Ayurvedic Medical Journal</i> , 2021, 9, 1452-1456.	0.0	0
1030	Common Dermatoses. , 2022, , 1653-1659.		0
1031	The Gene Expression Analysis of Peripheral Blood Monocytes From Psoriasis Vulgaris Patients With Different Traditional Chinese Medicine Syndromes. <i>Frontiers in Pharmacology</i> , 2021, 12, 759741.	1.6	2
1032	Manifestaciones orales en pacientes con psoriasis. Prevalencia y asociaci3n con sus caracter3sticas cl3nicas y epidemiol3gicas. <i>Actas Dermo-sifiligr3ficas</i> , 2022, 113, 459-466.	0.2	3
1033	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	1.4	30
1034	Role of Inflammatory Cytokines in Pathophysiology of Psoriasis. <i>Current Pharmacology Reports</i> , 2022, 8, 99-105.	1.5	4
1035	Psoriasis and uveitis. <i>International Ophthalmology</i> , 2022, 42, 2303-2310.	0.6	6
1036	Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates. <i>Emirates Medical Journal</i> , 2022, 3, 17-34.	0.3	0
1037	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. <i>Actas Dermo-sifiligr3ficas</i> , 2022, 113, T261-T277.	0.2	4
1040	Sex Differences in the Patterns of Systemic Agent use Among Patients With Psoriasis: A Retrospective Cohort Study in Quebec, Canada. <i>Frontiers in Pharmacology</i> , 2022, 13, 810309.	1.6	1
1041	Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	1.9	0
1042	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-106.	0.9	1
1043	Psoriasis and Pneumonia in the End-stage Renal Disease Population. <i>American Journal of the Medical Sciences</i> , 2022, , .	0.4	0
1044	Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. <i>Pharmaceutics</i> , 2022, 14, 654.	2.0	9

#	ARTICLE	IF	CITATIONS
1046	Can Biological Drugs Diminish the Risk of Sarcopenia in Psoriatic Patients? A Systematic Review. <i>Life</i> , 2022, 12, 435.	1.1	0
1047	Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece. <i>Dermatology Reports</i> , 0, , .	0.4	1
1048	The putative role of thyroid hormones and vitamin d on severity and quality of life in psoriasis. <i>International Journal of Applied & Basic Medical Research</i> , 2020, 10, 173.	0.2	2
1050	Manifestaciones orales en pacientes con psoriasis. Prevalencia y asociaci3n con sus caracter3sticas cl3nicas y epidemiol3gicas. <i>Actas Dermo-sifiligr3ficas</i> , 2022, , .	0.2	1
1056	Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis. <i>Clinical and Experimental Medicine</i> , 2023, 23, 701-715.	1.9	1
1057	Psoriasis at the time of COVID-19: results of an Italian survey on patients and caregivers. <i>AboutOpen</i> , 0, 9, 29-35.	0.2	0
1058	Performance of Coronary Artery Calcium Testing in Patients With Severe Psoriasis: Risk Assessment and Reclassification Potential in a Low Cardiovascular Risk Population. <i>Actas Dermo-sifiligr3ficas</i> , 2022, 113, 773-780.	0.2	2
1059	Exploration of the Potential Mechanism of the Common Differentially Expressed Genes in Psoriasis and Atopic Dermatitis. <i>BioMed Research International</i> , 2022, 2022, 1-16.	0.9	1
1060	Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
1061	Neurologic adverse effects from dermatologic drugs. , 2013, , 711-717.e2.		1
1062	Pathogenic aspects of treatment of psoriatic patients. <i>Vestnik Dermatologii I Venerologii</i> , 2014, 90, 86-90.	0.2	5
1063	Selective intracellular inhibition of signalling pathways - new direction in systematic treatment of psoriasis patients. <i>Vestnik Dermatologii I Venerologii</i> , 2016, 92, 55-62.	0.2	1
1064	The role of YKL-40 in the pathogenesis of autoimmune diseases: a comprehensive review. <i>International Journal of Biological Sciences</i> , 2022, 18, 3731-3746.	2.6	23
1065	Deep Sequencing of Plasma Exosomal microRNA Level in Psoriasis Vulgaris Patients. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
1066	Importance and prospects of studying survival of genetically engineered biological therapy for psoriasis in children. <i>Medical Alphabet</i> , 2022, , 80-85.	0.0	2
1067	4â€fThe psoriasiform reaction pattern. , 2010, , 49-67.		0
1068	Part I: Interactive case: Psoriasis. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 644-648.	0.5	0
1069	Chinese and Western Herbal Medicines for the Topical Treatment of Psoriasis-a critical review of Efficacy and Safety. <i>Journal of Herbal Medicine</i> , 2022, , 100579.	1.0	1

#	ARTICLE	IF	CITATIONS
1070	Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study. <i>Anais Brasileiros De Dermatologia</i> , 2022, 97, 566-574.	0.5	2
1071	Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 1777-1792.	1.4	22
1072	Calcipotriol/betamethasone aerosol foam (Enstilum) for the topical treatment of psoriasis vulgaris in routine practice in Korea: A prospective, noninterventional, multicenter study of treatment outcomes and patient satisfaction. <i>Journal of Dermatology</i> , 2022, 49, 1085-1095.	0.6	3
1074	Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. <i>Journal of Controlled Release</i> , 2022, 349, 354-366.	4.8	12
1075	Psychological Profile of Patients with Psoriasis. <i>Annals of the Academy of Medicine, Singapore</i> , 2018, 47, 516-522.	0.2	28
1076	Seasonal Patterns and Trends in Dermatoses in Poland. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8934.	1.2	1
1077	Updated Role of High-frequency Ultrasound in Assessing Dermatological Manifestations in Autoimmune Skin Diseases. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00765.	0.6	4
1078	Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting. <i>Journal of Dermatological Treatment</i> , 2022, 33, 3178-3187.	1.1	1
1079	Risk for incident suicidality among psoriasis patients: a systematic review and meta-analysis. <i>Archives of Dermatological Research</i> , 2023, 315, 455-465.	1.1	6
1080	Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNF \pm -inhibitors in patients with inflammatory rheumatic diseases (IRDs). <i>Expert Opinion on Drug Safety</i> , 0, , 1-8.	1.0	0
1081	Real-world health outcomes in US adult patients with mild to moderate plaque psoriasis taking topical therapy. <i>Journal of Dermatological Treatment</i> , 0, , 1-9.	1.1	0
1082	Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies. <i>Postepy Dermatologii I Alergologii</i> , 2023, 40, 165-170.	0.4	1
1083	Commentary: A clinician should know about systemic psoriasis and eye. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 3332.	0.5	0
1084	Xiyanping injection combined with acitretin for psoriasis vulgaris: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1085	Mitochondrial dysfunction: The pathological link between psoriasis and insulin resistance?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 340-347.	1.3	2
1086	Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Propionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis. <i>Dermatology and Therapy</i> , 2022, 12, 2589-2600.	1.4	2
1087	Dickkopf-1 as a promising therapeutic target for autoimmune diseases. <i>Clinical Immunology</i> , 2022, 245, 109156.	1.4	6
1088	Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis. <i>Current Opinion in Pharmacology</i> , 2022, 67, 102292.	1.7	4

#	ARTICLE	IF	CITATIONS
1089	Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles. Computational and Structural Biotechnology Journal, 2022, 20, 6097-6107.	1.9	16
1090	Results of an observational study in patients with psoriasis vulgaris who received long-term topical therapy (PSO-CONTROL). Klinicheskaya Dermatologiya I Venerologiya, 2022, 21, 610.	0.0	0
1091	Impact of Season and Other Factors on Initiation, Discontinuation, and Switching of Systemic Drug Therapy in Patients with Psoriasis: A Retrospective Study. JID Innovations, 2023, 3, 100171.	1.2	0
1092	Psoriasis: A Case Report. , 2022, 1, 26-30.		0
1093	The comprehensive role of apoptosis inhibitor of macrophage (AIM) in pathological conditions. Clinical and Experimental Immunology, 2023, 212, 184-198.	1.1	3
1094	An optical system for noninvasive microscopy of psoriatic mice in vivo. Journal of Biophotonics, 2023, 16, .	1.1	0
1095	Vitamin D Receptor Gene Polymorphism Apal as a Predisposing Factor for Psoriasis and Its Relation With Serum Vitamin D Levels and Psoriasis Severity. Cureus, 2022, , .	0.2	3
1096	Nanoscale Topical Pharmacotherapy in Management of Psoriasis: Contemporary Research and Scope. Journal of Functional Biomaterials, 2023, 14, 19.	1.8	4
1097	Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways. European Journal of Pharmacology, 2023, 947, 175668.	1.7	8
1098	Elementos clave de la inmunogenética de la psoriasis. Iatreia, 2014, 27, 439-448.	0.1	0
1099	Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies. Journal of Dermatological Treatment, 2023, 34, .	1.1	2
1100	Genetically engineered biological therapy for psoriasis in patients with a history of cancer: a literature review and case report. Klinicheskaya Dermatologiya I Venerologiya, 2023, 22, 57.	0.0	0
1102	Artificial Intelligence-Based Psoriasis Severity Assessment: Real-world Study and Application. Journal of Medical Internet Research, 0, 25, e44932.	2.1	8
1103	Palbociclib blocks neutrophilic phosphatidylinositol 3-kinase activity to alleviate psoriasiform dermatitis. British Journal of Pharmacology, 2023, 180, 2172-2188.	2.7	3
1128	The extracellular matrix of the skin: systemic diseases with local manifestations. , 2024, , 459-472.		0